

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number  
**WO 01/97850 A2**

BEST AVAILABLE COPY

- (51) International Patent Classification<sup>7</sup>: **A61K 45/06**
- (21) International Application Number: PCT/EP01/06976
- (22) International Filing Date: 20 June 2001 (20.06.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
00250194.8 23 June 2000 (23.06.2000) EP  
00250214.4 28 June 2000 (28.06.2000) EP
- (71) Applicant: **SCHERING AKTIENGESELLSCHAFT**  
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).
- (71) Applicants and  
(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimerswalder Steig 26, 13503 Berlin (DE). **HABEREY, Martin** [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIERAUCH, Karl-Heinz** [DE/DE]; Hochwildpfad 45, 14169 Berlin (DE).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/97850 A2

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**Combinations and compositions which interfere with VEGF/ VEGF and  
angiopoietin/ Tie receptor function and their use (II)**

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their  
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of  
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PlGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an  
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1  
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during  
10 early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce  
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also  
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and  
25 lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was  
30 observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

- VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).
- 10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4
- 15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high
- 20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2
- 25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).
- Interference with Tie2 receptor function by means of Angiopoietin-neutralizing
- 30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).
- Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 5 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. 10 Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 15 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

20 However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon 25 combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby 30 sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or  
5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological  
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor  
15 systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the  
20 receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents  
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhuMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.

Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.


30

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).



Examples for delivery-/Targeting-Systems have been described as ligand/  
 antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59,  
 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell  
 targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-  
 5 8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998),  
 Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example  
 molecules of general formula I



I,

in which


$r$  has the meaning of 0 to 2,

$n$  has the meaning of 0 to 2;

$R_3$  und  $R_4$  a) each independently from each other have the meaning  
 of lower alkyl,

9

b) together form a bridge of general partial formula II,




5

m

wherein the binding is via the two terminal C- atoms, and  
has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

10



15

G

20

A, B, D, E and T

25

wherein one or two of the ring members  $T_1, T_2, T_3, T_4$  has the  
meaning of nitrogen, and each others have the meaning of  
CH, and the bining is via the atoms  $T_1$  and  $T_4$ ;

has the meaning of  $C_1 - C_6$  - alkyl,  $C_2 - C_6$  - alkylene or  
 $C_2 - C_6$  - alkenylene; or  $C_2 - C_6$  - alkylene or  $C_3 - C_6$  - alkeny-  
lene, which are substituted with acyloxy or hydroxy;  $-CH_2-O-$ ,  
 $-CH_2-S-$ ,  $-CH_2-NH-$ ,  $-CH_2-O-CH_2-$ ,  $-CH_2-S-CH_2-$ ,  
 $-CH_2-NH-CH_2$ , oxa ( $-O-$ ), thia ( $-S-$ ) or imino ( $-NH-$ ),

independently from each other have the meaning of N or CH ,  
with the provisio that not more than three of these  
Substituents have the meaning of N,

- Q has the meaning of lower alkyl, lower alkyloxy or halogene,  
R<sub>1</sub> and R<sub>2</sub> independently from each other have the meaning of H or lower alkyl,
- X has the meaning of imino, oxa or thia;
- 5 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
- Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated
- 10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
- 15 more than one rest Z is present ( $m \geq 2$ ), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.


These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.

25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenese, respectively, which results in a prevention of tumor growth and tumor spread, are for example

anthranil acid derivatives of general formula IV

30



in which

A

has the meaning of group  $=NR^2$ ,

5


W

has the meaning of oxygen, sulfur, two hydrogen atoms or the group  $=NR^8$ ,

Z

has the meaning of the group  $=NR^{10}$  or  $=N-$ ,  $-N(R^{10})-$ ,  $(CH_2)_q-$ , branched or unbranched  $C_{1-6}$ -Alkyl or is the group


10



15

or A, Z and  $R^1$  together form the group

20



m, n and o

q

R<sub>a</sub>, R<sub>b</sub>, R<sub>c</sub>, R<sub>d</sub>, R<sub>e</sub>, R<sub>f</sub>

5

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C<sub>1-4</sub> alkyl or the group =NR<sup>10</sup>, and/or R<sub>a</sub> and/or R<sub>b</sub> together with R<sub>c</sub> and/or R<sub>d</sub> or R<sub>e</sub> together with R<sub>e</sub> and/or R<sub>f</sub> form a bound, or up to two of the groups R<sub>a</sub>-R<sub>f</sub> form a bridge with each up to 3 C-atoms with R<sup>1</sup> or R<sup>2</sup>,

10

X

has the meaning of group =NR<sup>9</sup> or =N-,

Y

has the meaning of group -(CH<sub>2</sub>)<sub>p</sub>,

p

has the meaning of integer 1-4,

R<sup>1</sup>

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C<sub>1-6</sub>-

15

alkyl, or C<sub>1-6</sub>-alkyl or C<sub>1-6</sub>-alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,

R<sup>2</sup>

has the meaning of hydrogen or C<sub>1-6</sub>-alkyl, or form a bridge with up to 3 ring atoms with R<sub>a</sub>-R<sub>f</sub> together with Z or R<sub>1</sub>,

20

R<sup>3</sup>


has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C<sub>1-6</sub>-alkyl, C<sub>1-6</sub>-alkoxy or hydroxy,

25

R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup>

independently from each other have the meaning of hydrogen, halogen or C<sub>1-6</sub>-alkoxy, C<sub>1-6</sub>-alkyl or


C<sub>1-6</sub>-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R<sup>5</sup> and R<sup>6</sup> together form the group



- 5            R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup>            independently from each other have the meaning of hydrogen or C<sub>1-6</sub>-alkyl, as well as their isomers and salts.


10        These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V





- 15            V,  
in which  
R<sup>1</sup>            has the meaning of group





20




14



in which  $R^5$  is chloro, bromo or the group  $-OCH_3$ ,



in which  $R^7$  is  $-CH_3$  or chloro,



in which  $R^8$  is  $-CH_3$ , fluoro, chloro or  $-CF_3$


in which  $R^4$  is fluoro, chloro, bromo,  $-CF_3$ ,  $-N=C$ ,  $-CH_3$ ,  $-OCF_3$  or  $-CH_2OH$

in which  $R^6$  is  $-CH_3$  or chloro

5

$R^2$

has the meaning of pyridyl or the group



10

and

$R^3$

has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

15

These compounds have the same properties as already mentioned above under compound IV and can be used for the treatment of angiogeneous diseases. Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

20

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

25

Claimed matter of the instant invention are therefor pharmaceutical compositions



a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg.

The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

- Combined functional interference with VEGF/VEGF receptor systems and with
- 5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
- 10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.
- 15 The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.
- 20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
- 25 tyrosine kinases Tie1 and Tie2.

- Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of
- 30 the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections  
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

## 5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with  $1 \times 10^6$  transfected  
15 A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,  
20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm<sup>2</sup> (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
- 10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm<sup>2</sup> to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen
- 15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm<sup>2</sup> to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.



**Example 2**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in  
 5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of  
 10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its  
 15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000  
 20 mm<sup>3</sup> within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm<sup>3</sup> within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

**Example 3**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing

10 recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons

15 when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

**Example 4**

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm<sup>3</sup>. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm<sup>3</sup> within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

**Example 5**

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to  
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-  
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in *E. coli* as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.  
 15 200 mm<sup>3</sup> animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+



Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a  
5 volume of approx. 450 mm<sup>3</sup> within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm<sup>2</sup>, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF  
10 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

**Example 6**

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to  
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-  
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm<sup>3</sup> animals receiving compound II were treated with a single  
15 intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm<sup>3</sup>. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm<sup>3</sup> within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm<sup>3</sup>. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm<sup>3</sup> within 28 days.

Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm<sup>3</sup> within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

### Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the  
 5 Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of  
 15 VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

20 Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

25

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-  
 30 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

## CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I  
which modulate the biological function of one or several of the VEGF/VEGF  
5 receptor systems, and comprising one or several agents as compound II which  
modulate the biological function of one or several of the Angiopoietin/Tie  
receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I  
10 which are targeted to the endothelium via one or several of the VEGF/VEGF  
receptor systems, and comprising one or several agents as compound II which  
modulate the biological function of one or several of the Angiopoietin/Tie  
receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I  
which modulates the biological function of one or several of the VEGF/VEGF  
receptor systems or of one or several of the Angiopoietin/ Tie receptor systems  
and comprising one or several agents as compound II which are targeted to  
the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I  
which modulate the biological function of one or several of the VEGF/VEGF  
receptor systems, and comprising one or several agents as compound II which  
are targeted to the endothelium via one or several of the Angiopoietin/Tie  
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I  
which are targeted to the endothelium via one or several of the VEGF/VEGF  
receptor systems, and comprising one or several agents as compound II which  
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie  
receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound  
I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,  
b) compounds which inhibit ligand binding to receptors,  
c) compounds which inhibit activation of intracellular signal pathways of the receptors,  
d) compounds which inhibit or activate expression of a ligand or of a  
25 receptor of the VEGF or Tie receptor system,  
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor  
30 systems,  
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.



11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a


14. Pharmaceutical compositions according to claims 1-11 which comprise as

25 compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as

30 compound I and/ or II at least one small molecule of general formula I

41



in which

5

r

has the meaning of 0 to 2,

n


has the meaning of 0 to 2;

R<sub>3</sub> und R<sub>4</sub>

a) each independently from each other have the meaning of lower alkyl,

10

b) together form a bridge of general partial formula II,



15


wherein the binding is via the two terminal C- atoms,  
and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20



has wherein one or two of the ring members  $T_1, T_2, T_3, T_4$  the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms  $T_1$  and  $T_4$ ;

5 G has the meaning of  $C_1 - C_6$  - alkyl,  $C_2 - C_6$  - alkylene or  $C_2 - C_6$  - alkenylene; or  $C_2 - C_6$  - alkylene or  $C_3 - C_6$  - alkenylene, which are substituted with acyloxy or hydroxy;  $-CH_2-O-$ ,  $-CH_2-S-$ ,  $-CH_2-NH-$ ,  $-CH_2-O-CH_2-$ ,  $-CH_2-S-CH_2-$ ,  $-CH_2-NH-CH_2$ , oxa ( $-O-$ ), thia ( $-S-$ ) or imino ( $-NH-$ ),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

$R_1$  and  $R_2$  independently from each other have the meaning of H or lower alkyl,

X has the meaning of imino, oxa or thia;

20 Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and


Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl,

25 30 whereas, if more than one rest Z is present ( $m \geq 2$ ), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

or double bonds; or an N-oxide of said compound,  
 wherein one or more N-atoms carry an oxygen atom,  
 or a salt thereof,

and/or a compound of general formula IV


5



in which

- A has the meaning of group  $=NR^2$ ,
- W has the meaning of oxygen, sulfur, two hydrogen atoms or the group  $=NR^8$ ,
- Z has the meaning of the group  $=NR^{10}$  or  $=N-$ ,  $-N(R^{10})-$ ,  $(CH_2)_q$ , branched or unbranched  $C_{1-6}$ -Alkyl or is the group


15



or A, Z and  $R^1$  together form the group

20


44



5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	R <sub>a</sub> , R <sub>b</sub> , R <sub>c</sub> , R <sub>d</sub> , R <sub>e</sub> , R <sub>f</sub>	independently from each other have the meaning of hydrogen, C <sub>1-4</sub> alkyl or the group =NR <sup>10</sup> , and/or R <sub>a</sub> and/or R <sub>b</sub> together with R <sub>c</sub> and/or R <sub>d</sub> or R <sub>c</sub> together with R <sub>e</sub> and/or R <sub>f</sub> form a bound, or up to two of the groups R <sub>a</sub> -R <sub>f</sub> form a bridge with each up to 3 C-atoms with R <sup>1</sup> or R <sup>2</sup> ,
10	X	has the meaning of group =NR <sup>9</sup> or =N-,
	Y	has the meaning of group -(CH <sub>2</sub> ) <sub>p</sub> ,
	p	has the meaning of integer 1-4,
15	R <sup>1</sup>	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C <sub>1-6</sub> -alkyl, or C <sub>1-6</sub> -alkyl or C <sub>1-6</sub> -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R <sup>2</sup>	has the meaning of hydrogen or C <sub>1-6</sub> -alkyl, or form a bridge with up to 3 ring atoms with R <sub>a</sub> -R <sub>f</sub> together with Z or R <sub>1</sub> ,
25	R <sup>3</sup>	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

$R^4, R^5, R^6$  and  $R^7$


substituted with one or more of für halogen,  $C_{1-6}$ -alkyl,  $C_{1-6}$ -alkoxy or hydroxy, independently from each other have the meaning of hydrogen, halogene or  $C_{1-6}$ -alkoxy,  $C_{1-6}$ -alkyl or  $C_{1-6}$ -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or  $R^5$  and  $R^6$  together form the group



$R^8, R^9$  and  $R^{10}$

independently from each other have the meaning of hydrogen or  $C_{1-6}$ -alkyl, as well as their isomers and salts,


and/ or a compound of general formula V



V,


in which

$R^1$  has the meaning of group




in which  $R^5$  is chloro, bromo or the group  $-OCH_3$ ,

5



in which  $R^7$  is  $-CH_3$  or chloro,



in which  $R^8$  is -CH<sub>3</sub>, fluoro,  
chloro or -CF<sub>3</sub>


in which  $R^4$  is fluoro,  
chloro, bromo, -CF<sub>3</sub>,  
-N=C, -CH<sub>3</sub>, -OCF<sub>3</sub> or  
-CH<sub>2</sub>OH

in which  $R^6$  is  
-CH<sub>3</sub> or chloro

5

$R^2$

has the meaning of pyridyl or the group



10

and

$R^3$

has the meaning of hydrogen or fluoro, as well as their  
isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as  
compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as  
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium  
hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF  
conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-  
phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-  
tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not  
identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as  
compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium



hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

- 5 19. Pharmaceutical compositions according to claims 1-17 which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.
- 10 20. Pharmaceutical compositions according to claims 1-17 which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.
21. Pharmaceutical compositions according to claims 1-17 which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.
- 15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
- 20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.
- 25




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

## Sequence Identifier

5

&lt;110&gt; Schering Aktiengesellschaft

10 <120> Combinations and compositions which interfere with VEGF/ VEGF and  
angiopoietin/ Tie receptor function and their use II

&lt;130&gt; 51867AEPM1XX00-P

&lt;140&gt;

15 &lt;141&gt;

&lt;160&gt; 59

&lt;210&gt; 1

20 &lt;211&gt; 1835

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 1

25

ttttacagtt ttccttttct tcagagttaa ttttgaattt tcatttttgg ataaccaagc 60  
agctcttttaa gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120  
tttctttttt ttttttaaat tttttttaat agtcacattc agctcgcttg ctcaaaccag 180  
actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240  
30 tatacaaaaca gccaaaaaac cataatgggt ccacagggat ggagcagga agggcatctc 300  
taacgtgtcc tctagtctat cttcgctaaa cagaaccac gttacacatg ataactagag 360  
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttaa 420  
aagcaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaaggggtt 480  
aagaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540  
35 tggagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600  
attaaaaggc ttggatgtta agagaggaca ctcagcgggt cctgaaggga gacgctgaga 660  
tggaccgctg agaagcggaa cagatgaaca caaagggaatc aaatctttac aaccaaaattg 720  
catttaagcg acaacaaaaa aaggcaaac ccaaacgca acctaaccac agcaaaatct 780  
aagcaaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840  
40 gagacgctac gtgccaacct aagtctctca cgacagcttc acagtaggat tattgtgata 900  
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960  
gtgatcgtaa gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatac 1020  
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggcgaca 1080  
tccgccaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140  
45 gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200  
ctccacgaac gggtagcgcg ttccatgaga aaggatattt ggcaatttta tattccacag 1260  
tcaggtaggg ctgcgatagc tcatttaatg ttaaagccca tcaggggcct ctcctccgt 1320  
ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggg 1380  
gggggctggc tgctggctcc gagggggcat ccgcagtcg tctggctcgtc tcctcctgca 1440  
50 ggctgggagc ctggccacca cttctccgac tcgacccttc caacaagcat cgcagggcac 1500  
tgtctcggg ggtacagacc gtggctccac attcgctacc actctgttcc acgtcatcca 1560  
ggtacacgag ctgcgtgtag gccgtgctgt ctggggctcg aggcctcttc tgctgggtgct 1620  
cttggacggg cgggtagttc tgctgcagag acaaagcacc tccccttccc ttccgggctg 1680  
atcttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740  
55 cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaag 1800  
gagacgaacc acgcccgggg gtgcggaagc ggcct

&lt;210&gt; 2

60 &lt;211&gt; 581

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 2

5 gttctagatt gttttattca gtaattagct ctttaagaccc ctggggcctg tgctacccag 60  
 acactaacia cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120  
 tcaacttact tcctgtggcc cattagggaa gtgggtgacct cgggagctat ttgcctgttg 180  
 agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240  
 tggcccggtta gcaagatata actatgcaat catgcaacaa agctgcctaa taacatttca 300  
 10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360  
 agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420  
 aaatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtgt gtgcgtatga 480  
 aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa ttagggccct 540  
 caccctccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3  
 <211> 516  
 <212> DNA  
 <213> Human

&lt;400&gt; 3

tagagatggt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60  
 tcagcccaga catgtgcatc tacatcacag aggacatgct catgtcgcgg aacctgaatg 120  
 gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180  
 25 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240  
 agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300  
 tcctgcgcat tgcaggctctg tgcaggaca ctgctcagag ttacaccttt ggatgtggcc 360  
 atgaactgga tgaggaaagg ctctatttga acagttgctt ggcccagcag tgcataca 420  
 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctactcatg 480  
 30 atgaagttcc agagtttgtt gtgtaaagtc cgtctg

<210> 4  
 <211> 1099  
 <212> DNA  
 35 <213> Human

&lt;400&gt; 4

cccacaacac agggggccctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60  
 40 cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120  
 ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180  
 ggggtgcgtc ttggccttgc cgtgccctca tcccccggtc gaggcagcga cacagcaggt 240  
 gcaccaactc cagcagggtta agcaccaggg agatgagtc aaccaccaac atgaagatga 300  
 tgaagatggt cttctccgtg gggcgagaga caaagcagtc cagcaggtag gggcagggtg 360  
 45 ctgctgggca cacaacacag ggctccatgg tccagccgta caggcgccac tggccataga 420  
 ggaagcctgc ctctagcaca ctcttgcaag gcacactggc gacatagggt cccatcagt 480  
 ctccgcggat gcgcaggcga ccactctctg ccaccgagat cttggccatc tgacgtctta 540  
 cggccgccag cgcccgctcc acctgtgggt ccttggccgg cagtggccgc agctccccct 600  
 ccttctgccg cagccgctct tctcgccgag acaggtaaat gacatggccc aggttagacca 660  
 50 ggggtgggtg gctgacgaag aggaactgca gcacccagta gcggatgtgg gagatgggga 720  
 aggcctgggt atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780  
 actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840  
 agagcaccgt cagccagatc ttaccacca cggtcgagtg ctctggacc tggccagca 900  
 acttctccac gaagccccag tcaaccatgg ctcccgggcc tccgtcggca aggagacaga 960  
 55 gcacgtcagt gtgtcagcat ggcatecttc tegtccgccc agcaacaagc ctgcagggag 1020  
 gtctgccacg cccgttctac cgctgcctg ccgggcggcc cagggtggag tggggacgat 1080  
 ggccggagtg acgcccgcg

<210> 5  
 60 <211> 1015  
 <212> DNA  
 <213> Human

&lt;400&gt; 5

65 gaggataggg agcctgggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

5 aaaaagtgct ttttgaaaat gttgaggttg aaatgatggg aaccaacatt ctttgattt 120  
 agtggggagc ataatagcaa acacccctt ggttcgcaca tgtacaggaa tgggacccag 180  
 ttggggcaca gccatggact tccccgccct ggaatgtgtg gtgcaaatg gggccagggc 240  
 ccagacccaa gaggagaggg tggctcgcag acacccggg atgtcagcat cccccgacct 300  
 10 gccttcttggc ggcacctccc ggggtgtgtg ttgagtcagc aggcattggg tgagagcctg 360  
 gtatatgctg ggaacagggt gcaggggcca agcggttcct cttcagcctt gacttggggc 420  
 atgcaccccc tctcccccaa acacaaacaa gcaatttctc agtatgggtg caggacaggt 480  
 gtccttccag tctctgtgtt atgacctcaa gtccacttgg ggcctgcag cccagcctgt 540  
 gttgtaacct ctgctcctc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600  
 15 atcatcattg ttgctttatc acttctaaga cattttgtac ggcacggaca agttaaacag 660  
 aatgtgcttc cctccctggg gtctcacacg ctcccacgag aatgccacag gggccgtgca 720  
 ctgggcaggc ttctctgtag aaccccaggg gcttcggccc agaccacagc gtcttggccc 780  
 gagcctagag cagggagtc cgaacttctg cattcacaga ccacctccac aattgttata 840  
 accaaaggcc tctgttctg ttatttctact taaatcaaca tgctattttg ttttactca 900  
 20 cttctgactt tagcctcgtg ctgagccgtg tatccatgca gtcattgtca cgtgctagtt 960  
 acgtttttct tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa  
  
 <210> 6  
 <211> 2313  
 <212> DNA  
 <213> Human  
  
 <400> 6  
  
 25 ccagagcagg cctggtggtg agcagggacg gtgcaccgga cggcgggatc gagcaaatgg 60  
 gtctggccat ggagcacgga gggctctacg ctccggcggg ggcagctct cggggctgct 120  
 ggtattacct cgcctacttc ttctctctcg tctccctcat ccaattcctc atcatcctgg 180  
 ggctcgtgct cttcatggtc tatggcaacg tgcacgtgag cacagagtcc aacctgcagg 240  
 30 ccaccgagcg ccgagccgag ggcctataca gtcagctcct agggctcacg gcctcccagt 300  
 ccaacttgac caaggagctc aacttcacca cccgcgcca ggtatgccatc atgcagatgt 360  
 ggctgaatgc tcgcccgcag ctggaccgca tcaatgccag cttccgcccag tgccagggtg 420  
 accgggtcat ctacacgaac aatcagaggt acatggctgc catcatcttg agtgagaagc 480  
 aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcattgtga 540  
 atcagaaggt gaagacgctg gaggtggaga tagccaagga gaagaccatt tgcactaagg 600  
 35 ataaggaaag cgtgctgctg aacaaacgcg tggcggagga acagctggtt gaatgctgta 660  
 aaacccggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaaggtgca 720  
 agccctctgc ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780  
 ggactccatt atcccacgca gcctggacaa cctgggttac aacctctacc atcccctggg 840  
 ctcggaattg gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900  
 40 ggtggaggag ctggcccggg gcctccgggg gatatcgaa cgcgtggccc gcgagaactc 960  
 agacctccaa gcccagaagc tggaagccca gcagggcctg cgggcccagtc aggaggcgaa 1020  
 acagaaggtg gagaaggagg ctcaggcccg ggaggccaag ctccaagctg aatgctcccg 1080  
 gcagaccag ctagcgtgag aggagaaggc ggtgctgcgg aaggaaacag acaacctggc 1140  
 caaggagctg gaagagaaga agagggaggc ggagcagctc aggatggagc tggccatcag 1200  
 45 aaactcagcc ctggacacct gcatcaagac caagtgcag ccgatgatgc cagtgtcaag 1260  
 gcccatgggc cctgtcccca acccccagcc catcgacca gctagcctgg aggagttcaa 1320  
 gaggaagatc ctggagtccc agaggccccc tgcaggcatc cctgtagccc catccagtgg 1380  
 ctgaggaggc tccaggcctg aggaccaagg gatggcccga ctccggcggtt tgcggaggat 1440  
 gcagggatat gctcacagcg cccgacacaa ccccctccc cgcgccccaa ccacccaggg 1500  
 50 ccaccatcag acaactccct gcatgcaaac cctagtacc ctctcacacc cgcaccggcg 1560  
 cctcacgac cctcaccag agcacacggc cgcggagatg acgtcacgca agcaacggcg 1620  
 ctgacgtcac atatcaccgt ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680  
 tatagcgtg gcgtcgtgca gatgcagcac gtcgcacaca gacatgggga acttggcatg 1740  
 acgtcacacc gagatgcagc aacgacgtca cgggcccatt cgagctcaca catattaatg 1800  
 55 tcacacagag cggcgatgg catcacacag acgggtatga tgctcacac agacacagtg 1860  
 acaacacaca ccatgacaac gacacctata gatatggcac caacatcaca tgcacgcatg 1920  
 ccctttcaca cacactttct acccaattct cacctagtgt cacgttcccc cgacctggg 1980  
 acacggggcca aggtacccac aggatcccat cccctcccgc acagccctgg gccccagcac 2040  
 60 ctccccctct ccagcttctt ggcctcccag ccacttctc acccccagtg cctggaccgg 2100  
 gaggtgagaa caggaagcca ttacactccg ctcttgagc gtgagtggtt ccaggacccc 2160  
 ctccggggccc tgagccgggg gtgaggggtc cctgttgtcg ggaggggagc cactccttct 2220  
 ccccaactc ccagccctgc ctgtggcccg ttgaaatgtt ggtggcactt aataaatatt 2280  
 agtaaactct taaaaaaaaa aaaaaaaaaa aaa

65 <210> 7  
 <211> 389



<212> DNA  
<213> Human

<400> 7

5

gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60  
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120  
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatatcat aggggactaa 180  
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240  
10 tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa tttttcgga 300  
gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggtct gaatttgttc 360  
tccttttgtg gtgtccagtg ggtaacatc

<210> 8

15

<211> 157  
<212> DNA  
<213> Human

<400> 8

20

tgcttttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggtttttag 60  
gaagcaggaa gcaagccac tcaaactgta aatttggcat gagggatcca gtaactttct 120  
cctcaatctg tgaactatat gtgagttga tttttg

25

<210> 9  
<211> 561  
<212> DNA  
<213> Human

30

<400> 9

aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60  
gatgttgttg gctgacatac aggctcagcc agcagagaaa gaattctgaa ttccccttgc 120  
tgaactgaac tattctgtta catatgggtg acaaatctgt gtgttatctt ttttctacct 180  
35 accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240  
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300  
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tttttgggt gatgatagtc 360  
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420  
ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgatc 480  
40 ttttctttaa aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540  
ctgcccacat ttctaggaaa a

<210> 10

45

<211> 1508  
<212> DNA  
<213> Human

<400> 10

50

cacaaacacg agagactcca cggctctgcct gagcaccgcc agcctcctag gctccagcac 60  
tcgcagggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120  
gggtcgcgga gcagtagcag gacaagtacc agcagcagct cctctgaaca gagactgcta 180  
ggatcatcct tctctccgg gctgttgct gatggcataa tccgggtgca acccaaatct 240  
gagctcaagc caggtgagct taagccactg agcaaggaag atttgggcct gcacgcctac 300  
55 aggtgtgagg actgtggcaa gtgcaaatgt aaggagtgca cctaccacag gcctctgcca 360  
tcagactgga tctgcgacaa gcagtgcctt tgctcgcccc agaactgat tgactatggg 420  
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480  
tgtgtctgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540  
gggtgtcatg cctctttttt gccttggtta tgggtgtacc ttccagccaa ggggtgcctt 600  
60 aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660  
aacacagttt gctgcaaaagt tcccactgtc ccccttagga actttgaaaa accaacatag 720  
catcattaat caggaatatt acagtaatga ggattttttt tttctttttt taatacacat 780  
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagtgtg gatagtcttt 840  
gctgtttgcg gtgaaatgct ttttgtccat gtgcccgttt aactgatatg cttgttagaa 900  
65 ctacgctaata ggagctcaaa gtatgagata cagaacttgg tgacccatgt attgcataag 960  
ctaaagcaac acagacactc ctaggcaaa tttttgtttg tgaatagtac ttgcaaaact 1020

tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatattttt 1080  
gtatatacaa taatatttgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140  
cacaaaatat tatactaata tgttgtagat tcggaagaat gtgaatcaat cagtatgttt 1200  
ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260  
5 ttcattgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320  
attgttttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaattttta 1380  
ttttaagagg catcttataa attttgcccc ttttatgagg atgtgatagt tgctgcaaat 1440  
gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500  
aaaaaaaa

10  
<210> 11  
<211> 389  
<212> DNA  
<213> Human

15  
<400> 11

20  
gggcagggtga tcagggcaca catttcccgt ccattgagac agtagcattc ccggcaccca 60  
tcgtgccagc tctcttcatt tttatgatga tgaccatcca cggtgagaca agtgcccgcac 120  
aggatgggtg gccagcgtga agcacaggcc gctctgcact tgcagataag acagccgtga 180  
ctgtcctgct ggaaccctaa ggggcagatc ttactgcatg agagctctgg acatttctta 240  
cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atactttgtca 300  
cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagtttttg 360  
acctcgccgc cgaccacgct gggtagcga

25  
<210> 12  
<211> 981  
<212> DNA  
<213> Human

30  
<400> 12

35  
tttttttttt ttggattgca aaaatttatt aaaattggag acactgtttt aatcttcttg 60  
tgccatgaga ctccatcagc cagctctaca agaccactgg gaggctgagg atcacttgag 120  
cccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180  
aagacccttt caagcagtaa gctgcatgct tgcttggtgt ggtcattaaa aaccctagtt 240  
taggataaca acatattaat cagggcaaaa tacaatgtg tgatgcttgt tagtagagta 300  
acctcagaat caaaatggaa cgggttttaca gtgatatcat tatatttcat ttggcagaat 360  
cattacatca ttgggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420  
40 taggataaca ggtctgcctg tttgaagatg aaaaataata ccattttaa atttgccta 480  
ctcaatttcc ttctcagta cattttaact tttaaacagc taatcactcc catctacaga 540  
ttaagggtgta tatgccacca aaaccttttg ccaccttaa aatttccttc aaagttttaa 600  
ctaattgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660  
cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720  
45 taccaggagc agaaccatta agctggtcca ggcaagttgg actccaccat ttcaacttcc 780  
agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840  
agtagctatt ctcatccttc cttggggaca caactgtcca taagggtgcta tccagagcca 900  
cactgcatct gcaccagca ccatacctca caggagtcca ctcccacgag ccgcctgtat 960  
ataagagtgc ttttgatgac g

50  
<210> 13  
<211> 401  
<212> DNA  
<213> Human

55  
<400> 13

60  
ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60  
aagagagccc ggccgcagag catgtgactg ctgggacctc tgggtagggc aacctgccc 120  
tctctccccc agagcgaccc ccggggcagg tcggggccca aggaatgacc cagcaactgc 180  
tccctaccca gcacactctc tttactgcca cctgcaatta tgctgtgaag atgactgggt 240  
gtgggtcatca cgattcagag aaatcaagat ctatgaccat tttaggcaaa gagagaaact 300  
tgagagaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcttc 360  
acttcagcat atttagttgt cattaaaatt aagctgatat t

65  
<210> 14

<211> 1002  
<212> DNA  
<213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60  
acagttgtgg agaacaggtt gagtagagca acaacaacaa aagcttatgc agtcaccttc 120  
tttgaaaatg ttaaatataa gtcctattct ctttgtccag ctgggttttag ctagaggtag 180  
10 ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaaagc caagttaact 240  
gaagtaaata tctggggccc atcgaccccc cactaagtac tttgtcacca tgttgtatct 300  
taaaagtcac ttttctactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360  
ttactccaaa ccagttttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420  
tggtctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480  
15 tactgaaaac aatggtgccca tatgctocaa agacatttcc ccaagataac tgccaaagag 540  
tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600  
attaatacag ctcaaatgga gtagtaacca agcttttctg ccaggaagt aacaaacatc 660  
actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacatc 720  
attcaataaa cattagccaa gctaagtgtc caagccactg tgccaggat taacaatata 780  
20 acaacaataa aagacacagt ccttcctctc aaggtgttca gtctagtagg gaagatgatt 840  
attcattaaa attttgggtg catcagaatc atgaggagct tgtcaaaaat gtaattcct 900  
gcctatgttc tcagatatc tggttaggtc aggagtggga acccaaatc aattctttta 960  
acaaacacta aaggtgatc taacacaggc ggtgtgagga cc

25 <210> 15  
<211> 280  
<212> DNA  
<213> Human

30 <400> 15

cgaggtgggc caccctgtgc tggctctgaga tttttaaatg aggattacat tatcctatct 60  
ataatattcc tattctaate tattgtattc ttacaattaa atgtatcaaa taattcttaa 120  
aaacattatt agaacaacac tgcctaatac cttataagac taaaaaaatc accaagatga 180  
35 aactgtatta tgactctcaa tatttaaaca tttaaaaaaa tgttagtggt tgttaagcac 240  
caatcctaac tatttcacct gcccgggcgg ccgctcgagg

<210> 16  
<211> 2041  
40 <212> DNA  
<213> Human

<400> 16

45 cccccgcag aactcccccc tggaaatagga tttttaaaac ccttgacaat tagaaatcct 60  
atagagggtta gcatttttta ggtaaaaaata tgggtgcccc tacagggatc atgcaacttc 120  
cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180  
atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240  
aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300  
50 atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaaaa gtattttttt 360  
ttaccttag catcaattct tttataaaga atgctaaata aattacattt tttgttcagt 420  
aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480  
caggtacata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540  
gaattttaag aggtagattt ttttccattg atgcattttg ttaataaatg tgtcaagaaa 600  
55 ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaga 660  
tagatatattg ttatagtctg acattttaac agtcatagta ttagacgttt cgtgaccagt 720  
gcatttttga ctctctcagg atcaaaaatac gagtctgccca actgtattaa atcctcctcc 780  
acccctcca ccagttgggtc cacagcttcc tgggtgggtcg ttgtcatcaa atccattggg 840  
ccgaaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactcttg 900  
60 ttcctgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960  
tggtctcca tttatccaga gtccactggt tgggttatta ccacttaaac cattagtact 1020  
atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tcgtaatttt 1080  
ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaa acccattctt 1140  
ttgacatttc cttaatttcc aaatcctgtt caaaaactgc actgggacta tctctcccta 1200  
65 gtaaatgact ctgggaggat gctaattgca gagcctcaga ctggtgtgac atctgatatg 1260  
aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320

5 taccagagtg aaccacaacg gaacttaata gatagggcac caattttgtg caggaagctt 1380  
 catcagtgccc tgaaggcttt aatttttttag caagggttctc actaagatca gtgaagtcaa 1440  
 catctacaga ccaactttct gacaatgaag agaaagaagt aattcttcta actggcaact 1500  
 ccaaaaccag tggccagtga tacattgtct aaaattttcc ttctcacatg atacttctga 1560  
 10 tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctccgt gatttgcata 1620  
 gttttctcag ctttttgag agaggcacag ttttcacaat aatattggtt atcaccagta 1680  
 agaattctctg gagcccaaaa aataatttag taagtcagtt actgaaggty tggtttcacc 1740  
 tcccggtttc tgaggtagat ctttattaac aagaatcttg ttagattcgt tagggacaga 1800  
 agtggtttca gaacagtaaa actcattagg aggactgcct atgggttttt cattcacaag 1860  
 15 tgagtcacag atgaaggcag ctgttggttg attataaact actggctcct ctgaaggacc 1920  
 gggtagacag gcttgcatga gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980  
 gacagacatg ttttccaaag aagaggaagc acaaaacgca agcgaaagat ctgtaaaaggc 2040  
 t

15 <210> 17  
 <211> 235  
 <212> DNA  
 <213> Human

20 <400> 17

cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagacccttc 60  
 acctctacaa ataaaaaatt aaaaaattag ccaggtgtgg cagcgaacaa ctgtagtctc 120  
 25 agatactcag gagactgagc tggaaaggat cacttgagcc caagaagttc aaggttacag 180  
 tgggccacga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta

<210> 18  
 <211> 2732  
 <212> DNA  
 30 <213> Human

<400> 18

35 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60  
 tcatgttgat aactacttta tatggagctt cattggacct gttaccttca ttattctgct 120  
 aaatattatc ttcttggtga tcacattgtg caaaatgggtg aagcattcaa acactttgaa 180  
 accagattct agcaggttgg aaacatttaa gtcttgggtg cttggcgctt tctgctttct 240  
 gtgtcttctt ggcctcacct ggtccttgg gttgcttttt attaatgagg agactattgt 300  
 gatggcatat ctcttcacta tatttaattgc ttccaggga gtgttcattt tcatctttca 360  
 40 ctgtgctctc caaaagaaag tacgaaaaga atatggcaag tgcttcagac actcactg 420  
 ctgtggagcg ctcccaactg agagtcccca cagttcagtg aaggcatcaa ccaccagaac 480  
 cagtgtctgc tattcctctg gcacacagag tctgataaga agaattgtga atgatactgt 540  
 gagaaaaaaa tcagaatctt cttttatctc aggtgacatc aatagcactt caacacttaa 600  
 tcaaggtggc ataaatctta atatattatt acaggactga catcacatgg tctgagagcc 660  
 45 catcttcaag atttatatca tttagaggac attcactgaa caatgccagg gatacaagt 720  
 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgtg cacaaggggtg 780  
 actataatga cagcgtgcaa gttgtggact gtggactaag tctgaatgat actgcttttg 840  
 agaaaatgat catttcagaa tttagtcaca acaacttacg gggcagcagc aagactcaca 900  
 acctcgagct cacgctacca gtcaaactg tgattggagg tagcagcagt gaagatgatg 960  
 50 ctattgtggc agatgcttca tctttaatgc acagcgacaa cccagggtctg gagctccatc 1020  
 acaaagaact cgaggcacca cttattcttc agcggactca ctcccttctg tacciaacccc 1080  
 agaagaaagt gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagagggtg 1140  
 aagatcacct acagtcccc aacagagact ctctttatac aagcatgccc aatcttagag 1200  
 actctcccta tccggagagc agccctgaca tggaaagaaga cctctctccc tccaggagga 1260  
 55 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320  
 agatgtgcta ccagatcagc aggggcaata gtgatggtta tataatcccc attaacaaga 1380  
 aagggtgtat tccagaagga gatgttagag aaggacaaat gcagctgggtt acaagtcttt 1440  
 aatcatcacg ctaaggaatt ccaagggcca catgcgagta ttaataaata aagacaccat 1500  
 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgtggttctc 1560  
 60 tgggtgtaaaa aagatgactg aaccttgtag ttctgtgaat ttttataaaa catacaaaaa 1620  
 ctttgtatat acacagagta tactaaagtg aattatttgt tacaagaaga agagatgcca 1680  
 gccaggtatt ttaagattct gctgctgttt agagaaattg tgaaacaagc aaaacaaaa 1740  
 tttccagcca ttttactgca gcagtctgtg aactaaattt gtaaatatgg ctgcaccatt 1800  
 tttgtaggcc tgcattgtat tatatacaag acgtaggctt taaaatcctg tgggacaaat 1860  
 65 ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagatat tctgcatcag 1920  
 tttgcagttc actgcaaatc ttttacatta agggcaagat tgaaaaacat ctttaaccact 1980

5 agcaatcaag ccacaggcct tatttcatat gtttcctcaa ctgtacaatg aactattctc 2040  
 atgaaaaatg gctaaagaaa ttatatattt ttctattgct agggtaaaat aaatacattt 2100  
 gtgtccaact gaaatataat tgtcattaaa ataattttta agagtgaaga aaatattgtg 2160  
 aaaagctott ggttgacacat gttatgaaat gttttttctt acactttgtc atggtaagtt 2220  
 ctactcattt tcaacttcttt tccactgtat acagtgttct gctttgacaa agttagtctt 2280  
 tattacttac atttaaattt cttattgcca aaagaacgtg ttttatgggg agaaacaaac 2340  
 tctttgaagc cagttatgtc atgccttgca caaaagtgtg gaaatctaga aaagattgtg 2400  
 tgtcaccctt gtttattctt gaacagaggg caaagagggc actgggcact tctcacaac 2460  
 tttctagtga acaaaagggt cctattcttt tttaaaaaa taaaataaaa cataaatatt 2520  
 10 actcttccat attccttctg cctatatatta gtaattaatt tattttatga taaagttcta 2580  
 atgaaatgta aattgtttca gcaaaattct gcttttttt catcccttg tgtaaaccctg 2640  
 ttaataatga gcccatcact aatatccagt gtaaagttaa acacggttg acagtaaata 2700  
 aatgtgaatt ttttcaagtt aaaaaaaaaa aa

15 <210> 19  
 <211> 276  
 <212> DNA  
 <213> Human

20 <400> 19

25 ctccctaaat gattttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60  
 aaccgccttt gcatattttt tatgtacaaa tctttgtata caattccgat gttccttata 120  
 tattccctat atagcaaacc aaaaccagga cctcccaact gcatgcctca agtccctgtg 180  
 gagcactctg gcaactggat ggccctactt gctttctgac aaaatagctg gaaaggagga 240  
 gggaccaatt aaatacctcg gccgcgacca cgctgg

30 <210> 20  
 <211> 2361  
 <212> DNA  
 <213> Human

<400> 20

35 attgtaccag ccttgatgaa cgtggggccct gcttcgcttt tgagggccat aagctcattg 60  
 cccactgggt tagaggctac cttatcattg tctcccgta ccggaaggtt tctcccaagt 120  
 cagagttttac cagcagggtat tcacagagct ccgacaagca gattctaaac atctatgacc 180  
 tgtgcaacaa gttcatagcc tatagcaccg tctttgagga ttagtggtat gtgcttgctg 240  
 agtggggctc cctgtacgtg ctgacgcggg atgggcgggt ccacgcactg caggagaagg 300  
 40 acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgattaac 360  
 ttgccaagag ccagcatctg gacagtgtg ggctggccca gattttcatg cagtatggag 420  
 accatctcta cagcaagggt aaccacgatg gggctgtcca gcaatatac cgaaccattg 480  
 gaaagttgga gccatcctac gtgatccgca agtttctgga tgcccagcgc attcacaacc 540  
 tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccgac cataccacc 600  
 45 tgctcctcaa ctgtataacc aagctcaagg acagctcgaa gctggaggag ttcataaga 660  
 aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaagggtc ctccggcagg 720  
 ctggctacta ctcccatgcc ctgtatctgg cggagaacca tgcacatcat gagtggtagc 780  
 tgaagatcca gctagaagac attaagaatt atcaggaagc ccttcgatac atcggaagc 840  
 tgccttttga gcaggcagag agcaacatga agcgtctagg caagatcctc atgcaccaca 900  
 50 taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg ccagcctcg 960  
 aaggccgcag cgatagggag gccccaggct gcagggccaa ctctgaggag ttcattccca 1020  
 tctttgccaa taaccgcgca gagctgaaag ctttcttaga gcacatgagt gaagtgcagc 1080  
 cagactcacc ccaggggatc tacgacacac tcttgagct gcgactgcag aactgggcc 1140  
 acgagaagga tccacaggtc aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200  
 55 gtggctcgctt cctgcagctc ttgacaagg ccctggctct gtgccagatg cagcacttcc 1260  
 aggatggtgt cctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcactacc 1320  
 acatgcagca cgagcagtag cggcaggtca tcagcgtgtg tgagcgccat ggggagcagg 1380  
 acccctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440  
 agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgcca cctctctag 1500  
 60 tgggtgcagc cctgggccac aactccacac ccacactctc cgtcatcagg gactacctg 1560  
 tccaaaaact acagaaacag agccagcaga ttgcacagga tgagctggg gtgcggcgg 1620  
 accgagagga gaccaccgt atccgccagg agatccaaga gctcaaggcc agtcctaaga 1680  
 ttttccaaa gaccaagtgc agcatctgta acagtgcctt ggagttgccc tcagtccact 1740  
 tctgtgtgg ccactccttc caccaacact gctttgagag ttactcggaa agtgatgctg 1800  
 65 actgccccac ctgcctcctt gaaaaaccga aggtcatgga tatgatccgg gcccggaac 1860  
 agaaacgaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920

ctgtgattgc tgactacttt ggagaggtg ttttcaacaa attgactctg ctgaccgacc 1980  
 ctcccacagc cagactgacc tccagcctgg aggcctgggt gcaacgcgac ctactcatgc 2040  
 actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100  
 agaacagaca caatgggacc tggcgggcg ttacacagaa ggctggctga catgcccagg 2160  
 5 gctccactct catctaattgt cacagcctc acaagactaa agcggaaact tttcttttcc 2220  
 ctggccttcc ttaattttta gtcaagcttg gcaatccctt cctctttaac taggcagggtg 2280  
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaacc tcctgaagtt 2340  
 ttggaaaaaa aagctggttt c

10 <210> 21  
 <211> 179  
 <212> DNA  
 <213> Human

15 <400> 21

aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60  
 acaatcaact aaaggaactg agagaaacct acaacacaca gcagttagcc cttgaacagc 120  
 tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

20 <210> 22  
 <211> 905  
 <212> DNA  
 <213> Human

25 <400> 22

tttttttttt ttctttaacc gtgtggtctt tatttcagtg ccagtgttac agatacaaca 60  
 caaatgttcc agtttagaagg aattcaaacg gaatgccaa gccaagcca ggctcaagaa 120  
 30 ataaaaaggg aggtttggag taatagataa gatgactcca atactcactc ttctaaggg 180  
 caaaggctact ttgatacag agtctgatct ttgaaactgg tgaactcctc ttccacccat 240  
 taccatagtt caaacaggca agttatgggc ttaggagcac tttaaaattt gtggtgggaa 300  
 tagggctcatt aataactatg aatatactct ttagaagggt accattttgc actttaaagg 360  
 gaatcaattt tgaaaatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420  
 35 gggagctgga agagccttgg aagtttctat tacaataaga gcacatata cttcatgcca 480  
 aatctcaaca aaagctcttt ttaactccat ctgtccagtg tttacaata aactcgcaag 540  
 gtctgaccag ttcttggtta caaacataca tgtgtgtgtc tgtgtgtata cagcaatgca 600  
 cagaaaaggc taccaggagc ctaatgcctc tttcaaacat tgggggaacc agtagaaaaa 660  
 ggcagggtc cctaattgtc attattacat ttccattccg aatgccagat gttaaaagtg 720  
 40 cctgaagatg gtaaccacgc tagtgaggaa taataacccc accttgccca gtccacagag 780  
 aaacaacagt agaaagaagg ggcaactctt tgctgcagag acaaagttag tgttttttcg 840  
 ccatggattg cagtcctctc ctccagacca gctgcttatt tcctcagggg cccaggggaat 900  
 gttga

45 <210> 23  
 <211> 2134  
 <212> DNA  
 <213> Human

50 <400> 23

ggtctcttct ttcctttttt tttttccaaa agtgttcttt tatttctagt aacatatatt 60  
 gtataaatac tctattttat atgcacttcc acaaaagcga tataatttaa aggttttttt 120  
 cattagaaat aaatgtataa aaataaataa gttattatag gcattttatta ctaactatag 180  
 55 tccttcttgg aaggaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240  
 tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300  
 accaggatac gactgttgga ccagctgctg gagatggacc tgctaccctc cagcagcctc 360  
 cccaccacaa gacaagtgat ctcaatgtcc ccaaacctgt gggaccctgt tctacacacc 420  
 tcatttttgt tccggcggtt catctcctt gtgtgattgt actgattttc atgagacaca 480  
 60 agttacttct ttacatccat attcccaaag cagggttaca tggtaggaaa gaaaggaagt 540  
 tggaggctact aagctcattg tgtctcctct agcttttacc agcatctaat gcttacttgc 600  
 tttttttcca ttgtagactt taatgcactt gaataaatac atggagttgt tttttcttca 660  
 aaatgaatta cacaaataaa gactgagatg gtccaaaaaa ggaagagga agccatttgc 720  
 gttattttcac gttgctgagc ctttctctca tgttgaaaca tctgaagttt taattctcgg 780  
 65 tagaaataat gtataaacat tctctgaaac catagcagcc ataaacagtg ctgggtcaag 840  
 atcctatttg tactcctttc tccccccatt gttagttagg taaagtaaaa cagggtcttag 900

5 taaaatctca cttttctcct acttttcatt tcccaacccc catgatacta agtattttgat 960  
 aagtaccagg aaacaggggt tgtaatatgt ctaacttttt ttgacaattg ctttgttttt 1020  
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccgg ggctttatta 1080  
 tgctatatca ctgctcagag gtttaataatc ctcactaact atcctatcaa atttgcaact 1140  
 10 ggcagttttac tctgatgatt caactccttt tctatctacc ccataatcc cactttactg 1200  
 atacacctca ctgggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260  
 gcaccagccc ttcctcactt tgccctgccc tcaaagctaa caccacttaa accacttaac 1320  
 tgcatctctg cattgtgcaa aagtctatga aatgttttagg tttcttttaa ggatcacagc 1380  
 tctcatgaga taacacccct ccatcatggg acagacactt caagcttctt tttttgtaac 1440  
 15 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500  
 ggtctgcaca aggtctggtg ctggctggct tcacttcctt tgcacactcg gaagcaggct 1560  
 gtccattaat gtctcgcat tctaccagtc tctctgcca acccaattca catgacttag 1620  
 aacattcgcc ccactcttca atgacctatg ctgaaaaagt ggggtagca ttgaaagatt 1680  
 ccttcttctt ctttacgaag taggtgtatt taatttttagg tcgaagggca ttgccacag 1740  
 20 taagaacctg gatggtcaag ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800  
 ccgcagagga gccgctgtac ctcaagacaa cacttttgta cataatgtct tgctctaagg 1860  
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920  
 agctgccatt gttcctggat cccctctggg tccgctgttt cacttcgatg ttgggtggctc 1980  
 cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040  
 25 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttcttttttg 2100  
 agtctatgat gcgatcaca ccagctttta caca

&lt;210&gt; 24

&lt;211&gt; 1626

25 &lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 24

30 ggacaatttc tagaatctat agtagtatca ggatatattt tgcttttaaaa tatatttttg 60  
 ttattttgaa tacagacatt ggctccaaat ttcatcttt gcacaatagt atgacttttc 120  
 actagaactt ctcaacattt gggaactttg caaatatgag catcatatgt gtttaaggctg 180  
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacagggt gaacaaacgt 240  
 agttgttttt tactgatact aaatgttggc tacctgtgat tttatagtat gcacatgtca 300  
 35 gaaaaaggca agacaaatgg cctctgttac tgaatacttc ggcaactta ttgggtcttc 360  
 attttctgac agacaggatt tgactcaata ttgttagagc ttgcgtagaa tggattacat 420  
 ggtagtgatg cactggtaga aatgggtttt agttattgac tcagaattca tctcaggatg 480  
 aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atggttttag 540  
 aaagctttgt ctaaaaattt ggccataggaa tggtaacttc attttcagtt gccaaagggt 600  
 40 agaaaaataa tatgtgtgtt gttatgttta tgtaacata ttattagta ctatctatga 660  
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720  
 ccatttagcc cagtgggaaa gtcttggaa tcagggttacc cttgaaggat atgctggcag 780  
 ccactctttt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840  
 tctggaatgc attagttagt ccttgtacca ttcccagaat ttcaggggca tctgtgggtt 900  
 45 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960  
 atcctaacta actggtcctc aactcaagca gaggttcttc actctggcac tgtgatcatg 1020  
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080  
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140  
 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200  
 50 cggtgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260  
 atggatttct ctatagctaa atgagttccc tctggggaga gttctggtac tgcaatcaca 1320  
 atgccagatg gtgtttatgg gctattttgt taagtaagtg gtaagatgct atgaagtaag 1380  
 tgtgtttgtt ttcactctat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440  
 tgggtcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500  
 55 atttaacctg tcacgttctt agttgcttca accattttat aaccattttt gtacatattt 1560  
 tacttgaaaa tatttttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620  
 aaaaaa

&lt;210&gt; 25

60 &lt;211&gt; 1420

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 25

65 gttcagcatt gtttctgctt ctgaaatctg tatagtagac tggtttgtaa tcattatgtc 60

5 ttcattgaaa tccttgctac ttctcttccct cctcaatgaa agacacgaga gacaagagcg 120  
 acacaagctt aagaaaaacg agcaaggaag agtatcttca ttattctcat tttctctgag 180  
 ttggaacaaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240  
 agtgggaaaaa ctttaagagt ttccacatat tagttttcat tttttgagtc aagagactgc 300  
 10 tccttgtagt gggagacact agtagtatat gtttgtaatg ttactttaaa attatctttt 360  
 ttttttataa ggcccataaa tactgggttaa actctgttaa aagtgggcct tctatcttgg 420  
 atggtttcac tgccatcagc catgctgata tattagaaat ggcaccccta tctacttact 480  
 ttaatgctta aaattatata taaaatgctt tattttagaaa acctacatga tacagtgggtg 540  
 tcagccttgc catgtatcag tttcacttga aatttgagac caattaaatt tcaactgttt 600  
 15 aggggtggaga aagaggtact ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660  
 atccttttga tgggaggaga gttactcttg aaaggcaggc agcttaagtg gacaatgttt 720  
 tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780  
 tttgctctgt tttgcctgaa gttttagtat ttgttttcta ggtggacctc tgaaaaccaa 840  
 accagtacct ggggaggtta gatgtgtgtt tcaggcttgg agtgtatgag tgggttttgc 900  
 20 tgtattttcc tccagagatt ttgaacttta ataattgcgt gtgtgttttt ttttttttaa 960  
 gtggctttgt ttttttttct caagtaaaat tgtgaacata tttcctttat aggggcaggg 1020  
 catgagttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgttct 1080  
 tcgacacatt ttttttcagt aacttgaaaa ttcaaaaggg acatttggtt aggttactgt 1140  
 acatcaatct atgcataaat ggcagcttgt tttcttgagc cactgtctaa attttgtttt 1200  
 25 tatagaaatt ttttatactg attggttcat agatggtcag ttttgtacac agactgaaca 1260  
 atacagcact ttgccaaaaa tgagtgtagc attgttttaa cattgtgtgt taacacctgt 1320  
 tctttgtaat tgggttgttg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380  
 agtaataaaa gtgtccttta acttcaaaaa aaaaaaaaaa

25 <210> 26  
 <211> 689  
 <212> DNA  
 <213> Human

30 <400> 26

35 aaacaaacaa aaaaaaagtt agtactgtat atgtaaatac tagcttttca atgtgctata 60  
 caaacaatta tagcacatcc ttccctttac tctgtctcac ctcccttagg tgagtacttc 120  
 ctaaaataag tgctaaacat acatatacgg aacttgaaag ctttggttag ccttgcccta 180  
 ggtaatcagc ctagttttaca ctgtttccag ggagtagttg aattactata aaccattagc 240  
 cacttgctctc tgcaccattt atcacaccag gacagggtct ctcaacctgg gcgctactgt 300  
 cattttggggc caggtgattc ttccctgcaa gggctgtcct gtacctgccg gggcgccgcg 360  
 tcgaagcgtg gtgcgcccgc aggtactgaa aggaccaagg agctctggct gccctcagga 420  
 40 attccaaatg accgaaggaa caaagcttca gggctctggg tgggtgtctcc cactattcag 480  
 gaggtggctg gaggtaacgc agcttcattt cgtccagtc tttccagtat ttaaagtgtg 540  
 tgtaaatgag ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaacatgt 600  
 ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctcctgaa tagtgggaga 660  
 cacaccacga gcctgaagtt tgtccttcg

45 <210> 27  
 <211> 471  
 <212> DNA  
 <213> Human

50 <400> 27

55 tcccagcggc atgaagtttg agattggcca ggccctgtac ctgggcttca tctccttcgt 60  
 ccctctcgct cattgggtggc accctgtctt gcctgtcctg ccaggacgag gcaccctaca 120  
 agccctaacc caggccccgc ccaggggccac cagcaccact gcaaacaccg cactgccta 180  
 ccagccacca gctgcctaca aagacaatcg ggcccccctca gtgacctcgg ccaccacagc 240  
 ggggtacaggc tgaacgacta cgtgtgagtc ccacagcct gcttctcccc tgggctgctg 300  
 tgggctgggt cccggcgagg ctgtcaatgg aggcaggggg tccagcacia agtttacttc 360  
 tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtctt tagagcacag 420  
 ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a

60 <210> 28  
 <211> 929  
 <212> DNA  
 <213> Human

65 <400> 28



5 ggtgaactca gtgcattggg ccaatggttc gacacaggct ctgccagcca caaccatcct 60  
 gctgcttctg acggtttggc tgctgggtgg ctttcccctc actgtcattg gaggcattct 120  
 tgggaagaac aacgccagcc cctttgatgc accctgtcgc accaagaaca tcgcccggga 180  
 gattccaccc cagccctggg acaagtctac tgcatccac atgactgttg gaggcttcct 240  
 gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300  
 gcagtacact ttgtacggca tcctcttctt tgtcttcgcc atcctgctga gtgtgggggc 360  
 ttgcatctcc attgactca cctacttcca gttgtctggg gaggattacc gctgggtgtg 420  
 10 gcgatctgtg ctgagtgttg gctccaccgg cctcttcac ttctctact cagttttcta 480  
 ttatgcccg cgctccaaca tgtctggggc agtacagaca gtagagttct tcggctactc 540  
 cttactcact ggttatgtct tcttctcat gctgggcacc atctcctttt tttcttcct 600  
 aaagttcatc cggatatct atgttaacct caagatggac tgagtctgt atggcagaac 660  
 tattgtgtt ctctcccttt cttcatgccc gttgaactc tcctaccagc ttctctctg 720  
 attgactgaa ttgtgtgat gcatgtgtgc cttccctttt tccctttggg cattccttc 780  
 15 ccagagaggg cctggaaatt ataatctct atcacataag gattatata ttgaactttt 840  
 taagttgcct ttagttttg tctgtattt tctttttaca attacaaaa taaaatttat 900  
 taagaaaaag aaaaaaaaa aaaaaaaa

<210> 29  
 20 <211> 1775  
 <212> DNA  
 <213> Human

25 <400> 29

30 gaacgtgatg ggaactttgg gaggatgtct gagaaaatgt ccgaagggat tttggccaac 60  
 accagaaaac gccaatgtcc taggaattcc ctcccaaat gcttcccaa aaattactca 120  
 ttgacaattc aaattgactc tggctggcgg cagcccgggc ggccttcagt ccgtgtggg 180  
 cgcccgcgtg gccttctcct cgtaggactc ccaaaactcg ttactctgc gtttatccac 240  
 35 aggataaagc caccgctggt acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300  
 cagccgggtga gacgtgggca tgggtgatgt gaaggcaag acgtcatcaa tgaagggtgt 360  
 gaaagccttg taggtgaagg ccttccaggg cagatgtgcc actgacttca acttgtagt 420  
 cacaagagc tggggcagca tgaagaggaa accaaaggca tagaccctgt tgacgaagct 480  
 gttgattaac caggagtacc agctcttata ttgatattc aggagtgaat agacagcacc 540  
 40 cccgacacag agaggggtaca gcaggtatga caagtacttc atggcctgag tatcgtactc 600  
 ctcggttttc ctctcagatt cgtgtgaagt cccaaactga aattcgggca tcaggcctct 660  
 ccaaaaaata gtcactttca atgccttctt cactttccac agctcaatgg cggctccaac 720  
 acccgccggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780  
 caccgtgctg aagcagcgcc agagcactgc cttggtggac atgccgatca tgctcttctt 840  
 45 cttcttccag aaactgatgt cattttttaa ggcaggaaa tcaaagagaa gatggaacgc 900  
 tgcgacaaag aaggtcagcg ccaggaagta taagttggt tctacaaaaa ttcctttcac 960  
 ctcacagca tctttctctg aaaacccgaa ctgctgcagg gactacacgg cgtcctgcat 1020  
 gtggatccag aagcgcagcc gccccagtga gaccttgctg taggacacgg tgaggggag 1080  
 ctcggtgggt gagcgggtta tgaccatcag gtccttcacg cgttgctga gctggctcat 1140  
 50 gaacaggatg ggcaggtaat gcacgggttt ccccagctgg atcatcttca tgtaccgatg 1200  
 cacatcggca ggcaggagg acccgtcaaa gacaaagtgt tccgccatca cgttcagcgc 1260  
 cagccgcggt cgccagtggg aactggctc atccaggga ctcgtcggct tcttctccgc 1320  
 ctcgatctgc tgtgtatcag actcccgggt gagcagggtt atttcttctg gcttggggac 1380  
 catgtagggt gtacagaggac tgaccaggtg cactgcttc ccgtcgtgcc acggcaggac 1440  
 55 cccagcgtga tggaggaaga tgtaggcata cagcgtccca ttgtttctcg ttttctttg 1500  
 tacagaaaac ttaactgtcc tttcaattt ggactccaca tcaaagtctt ccacattcaa 1560  
 gaccaggtcg atgttgttct cagcaccag gtgggacctc gtcgtggtgt acacgtcag 1620  
 ctgcagcttg ggccgccgcg ccaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680  
 gcggtgtag acgatgccgt acatgaccca gcagggtgtg accacgtaga ccacgaacac 1740  
 60 gcccaccacc aagctggtga aggagctgcg gccc

<210> 30  
 <211> 1546  
 <212> DNA  
 60 <213> Human

<400> 30

65 aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgcta 60  
 aaggccctgc caggctggga gggaattgtc cctgctgct tctggagaaa gaagatattg 120

5 acaccatcta cgggcacccat ggaactgctt caagtgaacca ttctttttct tctgcccagt 180  
 atttgagca gtaacagcac aggtgtttta gaggcagcta ataattcact tgttggtact 240  
 acaacaaaac catctataac aacaccaaac acagaatcat tacagaaaaa tgtgtgcaca 300  
 ccaacaactg gaacaactcc taaagggaaca atcaccaatg aattacttaa aatgtctctg 360  
 10 atgtcaacag ctactttttt aacaagtaaa gatgaaggat tgaaagccac aacctgat 420  
 gtcaggaaga atgactccat catttcaaac gtaacagtaa caagtgttac acttccaaat 480  
 gctgtttcaa cattacaaag ttccaaaccc aagactgaaa ctccagagttc aattaaaaa 540  
 acagaaatac caggtagtggt tctacaacca gatgcatcac cttctaaaaa tggtagatta 600  
 acctcaatac cagttacaat tccagaaaaac acctcacagt ctcaagtaat aggactgag 660  
 15 ggtggaaaaa atgcaagcac ttcagcaacc agccgggtctt attccagtat tattttgccg 720  
 gtggttattg ctttgattgt aataacactt tcagtatttg ttctggtggg tttgtaccga 780  
 atgtgctgga aggcagatcc gggcacacca gaaaatggaa atgatcaacc tcagtctgat 840  
 aaagagagcg tgaagcttct taccgttaag acaatttctc atgagctggt tgagcactct 900  
 gcacaaggaa aaaccaagaa ctgacagctt gaggaattct ctccacacct aggcaataat 960  
 20 tacgtttaat cttcagcttc tatgcacca gcgtggaaaa ggagaaagtc ctgcagaatc 1020  
 aatcccagct tccatacctg ctgctggact gtaccagacg tctgtcccag taaagtgatg 1080  
 tccagctgac atgcaataat ttgatggaat caaaaagaac cccggggctc tcctgttctc 1140  
 tcacatttaa aaattccatt actccattta caggagcgtt cctaggaaaa ggaattttag 1200  
 gaggagaatt tgtgagcagt gaatctgaca gccaggagg tgggctcgct gataggcatg 1260  
 25 actttcctta atgtttaaag ttttcgggc caagaatttt tatccatgaa gactttccta 1320  
 cttttctcgg tgttcttata ttacctactg ttagtattta ttgtttacca ctatgttaat 1380  
 gcagggaaaa gttgcacgtg tattatttaa tattaggtag aaatcatacc atgctacttt 1440  
 gtacatatata gtattttatt cctgctttcg tgttactttt aataaataac tactgtactc 1500  
 aatactctaa aaatactata acatgactgt gaaaatggca aaaaaa  
 30 <210> 31  
 <211> 750  
 <212> DNA  
 <213> Human  
 35 <400> 31  
 cacttgggca cccccatttt ctaaaaaaat ggaaatctgg agggcaaaaa aggtgtgctg 60  
 aagggaagtg cctctgatgg ccacaaaacc ttcttccaaa ctagtgtagg aatggaatgg 120  
 atagcaaatg gatccttttt ggccctcctt ggagcatgcc ttccctatct tatccttggc 180  
 40 cccactaaag cagaacgtta cggatatttc tgtttttgcc attggatgcc tatctggcca 240  
 aacagccttt ccctaattgg aaaatgcagt cctgtttaaa accttgatt tacgactact 300  
 tgtacatgct tgctcattac aattttgaca ttttttacct agtgaagacc ccaaaccatat 360  
 cagtgaacaa tgacaagatc ataaagaaca gtatcatatt attatttagt cgcttttaca 420  
 45 gtggcaagcc aattttgaaa tatctcattt aaaactcaga cccaattcac tgagtatac 480  
 ttttaatagc ttctcagca cactatttcc catgcattaa atatgataaa ataactatc 540  
 actgccatc ggtcttgtaa aaaggaagtc tgaatacaga gccacaaca ctaaaattgt 600  
 ttttctagct acaaagtata gcatcatcaa cacagacacg atttgactc cctgacaggt 660  
 ggattgaaa acggtgttta aagagaagag aacattttta cataaatgct attaagaatc 720  
 50 ccaaaggcct tatttgcac caccgtccc  
 <210> 32  
 <211> 1620  
 <212> DNA  
 55 <213> Human  
 <400> 32  
 gcaattcccc cctcccacta aacgactccc agtaattatg tttacaaccc attggatgca 60  
 55 gtgcagccat tcataagaac cttggtgccc cagaaaaatc tgtccttttt ggtaccacaa 120  
 ctgaggtctt ttggaagata atgtagaaaa ccactaccta ttgaaggcct gttttggcta 180  
 atctgtgcaa actctgatga tacctgcctt atgtggattc ttttccacac tgctttcatt 240  
 ttaagtata aagacttaga aaactagaat aatgctttta caaataatta aaagtatgtg 300  
 atgttctggg ttttttctt ctttttagaa ccccgctcc atttaaaaaa ttaaaaaaaa 360  
 60 aaaaaaaact ttaacattt aaaaaataaa aattaacaaa atttactta ttccaggaca 420  
 cgctggcatt tggactcaat gaaaagggca cctaaagaaa ataaggctga ctgaatgtt 480  
 tccataattt tcacacaata acagtccctt tctatccagc ttgccttcca tttatctcta 540  
 gggttagctt ttcaggcaac atccttggtc attgcccaga aagtacctga gctatcagt 600  
 attggaatgg cacaggaaac cgaatcacat ggggtgcctc cccttggtt tcaagtatct 660  
 65 tggagtgtg cacaataatt aggtcatgcc ttcaagtgtc tgttctttaa acctaccctt 720  
 tgacaatcag gtgctaataa ttgtatacta ttaaaaccag cacataagta ttgtaaatgt 780

	gtgttcctcc	taggttgga	gaaatgtctt	tccttctatc	tgggtcctgt	taaagcgggt	840
	gtcagttgtg	tcttttcacc	tcgattttgtg	aattaataga	attgggggga	gaggaaatga	900
	tgatgtcaat	taagtttcag	gtttggcatg	atcatcattc	tcgatgatat	tctcactttg	960
	tcgcaaatct	gcccttatcg	taagaacaag	tttcagaatt	ttccctccac	tatacgactc	1020
5	cagtattatg	tttacaatcc	attggatgag	tgcagcatta	taagaccttg	gtgccagaa	1080
	aaatctgtcc	tttttggtac	caaacctgag	gtccttttga	agataatgta	gaaaaccact	1140
	acctattgaa	ggcctgtttt	ggctaactctg	tgcaaacctc	gatgatacct	gcttatgtgg	1200
	attcctttcc	acactgcttt	cattttttaag	tataaagact	tagaaaaacta	gaataatgct	1260
	tttacaata	attaaaagta	tgtgatgttc	tgggtttttt	ccttcttttt	agaaccctgt	1320
10	atttaacaa	gccttctttt	taagtcttgt	ttgaaattta	agtctcagat	cttctggata	1380
	ccaaatcaaa	aacccaacgc	gtaaaacagg	gcagtatttg	tgttcctaat	tttaaaaagc	1440
	tttatgtata	ctctataaat	atagatgcac	caatgaaat	gtgtaactta	agggtattat	1500
	acatacagca	ttgtacatta	caatgaaat	gtgtaactta	agggtattat	atatataaat	1560
	acatatatac	ctttgtaacc	tttatactgt	aaataaaaaa	gttgctttag	tcaaaaaaaa	1620
15	<210> 33						
	<211> 2968						
	<212> DNA						
	<213> Human						
20	<400> 33						
	gaaaaagtag	aaggaaacac	agttcatata	gaagtaaaag	aaaaccctga	agaggaggag	60
	gaggaggaag	aagaggaaga	agaagatgaa	gaaagtgaag	aggaggagga	agaggaggga	120
25	gaaagtgaag	gcagtgaagg	tgatgaggaa	gatgaaaagg	tgtagatga	gaaggattca	180
	gggaagacat	tagataaaaa	gccaagtaaa	gaaatgagct	cagattctga	atatgactct	240
	gatgatgac	ggactaaaga	agaaagggt	tatgacaaag	caaaacggag	gattgagaaa	300
	cggcgacttg	aacatagtaa	aaatgtaaac	accgaaaagc	taagagcccc	tattatctgc	360
	gtacttgggc	atgtggacac	aggggaagaca	aaaattctag	ataagctccg	tcacacacat	420
30	gtacaagatg	gtgaagcagg	tggtatcaca	caacaaattg	gggccaccaa	tgttctctct	480
	gaagctatta	atgaacagac	taagatgatt	aaaaattttg	atagagagaa	tgtacggatt	540
	ccagggaatg	taattattga	tactcctggg	catgaatctt	tcagtaatct	gagaaataga	600
	ggaagctctc	tttgtgacat	tgccatttta	gttgttgata	ttatgcattg	tttggagccc	660
	cagacaattg	agtctatcaa	ccttctcaaa	tctaaaaaat	gtcccttcat	tgttgactct	720
35	aataagattg	ataggttata	tgattggaaa	aagagtcctg	actctgatgt	ggctgctact	780
	ttaaagaagc	agaaaaagaa	tacaaaagat	gaatttgagg	agcgagcaaa	ggctattatt	840
	gtagaatttg	cacagcaggg	tttgaatgct	gctttgtttt	atgagaataa	agatccccgc	900
	acttttgtgt	ctttggtacc	tacctctgca	catactgggtg	atggcatggg	aagtctgac	960
	taccttcttg	tagagttaac	tcagaccatg	ttgagcaaga	gacttgcaca	ctgtgaagag	1020
40	ctgagagcac	aggtgatgga	ggttaaagct	ctcccgggga	tgggcaccac	tatagatgct	1080
	atcttgatca	atgggcgttt	gaagggaagg	gatacaatca	ttgttcctgg	agtagaaggg	1140
	cccattgtaa	ctcagattcg	aggcctcctg	ttacctctc	ctatgaagga	attacgagtg	1200
	aagaaccagt	atgaaaagca	taaagaagta	gaagcagctc	agggggtaaa	gattcttgga	1260
	aaagacctgg	agaaaacatt	ggctggttta	cccctccttg	tggcttataa	agaagatgaa	1320
45	atccctgttc	taaaagatga	attgatccat	gagttaaagc	agacactaaa	tgctatcaaa	1380
	ttagaagaaa	aaggagtcta	tgtccaggca	tctacactgg	gttcttttga	agctctactg	1440
	gaatttctga	aaacatcaga	agtgccctat	gcaggaatta	acattggccc	agtgcataaa	1500
	aaagatgtta	tgaaggtctc	agtgatgttg	gaacatgacc	ctcagtatgc	agtaattttg	1560
	gccttcgatg	tgagaattga	acgagatgca	caagaaatgg	ctgatagttt	aggagttaga	1620
50	atttttagtg	cagaaattat	ttatcattta	tttgatgcct	ttacaaaata	tagacaagac	1680
	tacaagaaac	agaaacaaga	agaatttaag	cacatagcag	tatttccctg	caagataaaa	1740
	atcctccctc	agtacatttt	taattctcga	gatccgatag	tgatgggggt	gacgggtgga	1800
	gcaggtcagg	tgaacacagg	gacacccatg	tgtgtcccaa	gcaaaaattt	tgttgacatc	1860
	ggaatagtaa	caagtattga	aataaacatt	aaacaagtgg	atgttgcaaa	aaaaggacaa	1920
55	gaagtttgtg	taaaaaataga	acctatccct	ggtagtcac	ccaaaatgtt	tgggaagacat	1980
	tttgaagcta	cagatattct	tgttagtaag	atcagccggc	agtcatttga	tgcactcaaa	2040
	gactggttca	gagatgaaat	gcagaagagt	gactggcagc	ttattgtgga	gctgaagaaa	2100
	gtatttgaaa	tcactctaatt	ttttcacatg	gagcaggaac	tggagttaa	gcaatactgt	2160
	gttgtaatat	cccaacaaa	atcagacaaa	aaatggaaca	gacgtatttg	gacactgatg	2220
60	gacttaagta	tgggaaggag	aaaaataggt	gtataaaatg	ttttccatga	gaaaccaaga	2280
	aacttacact	ggtttgacag	tggtcagtta	catgtcccca	cagttccaat	gtgcctgttc	2340
	actcacctct	cccttcccca	acccttctct	acttggtctc	tgttttaaa	tttgccttcc	2400
	cccaattttg	gattttttatt	acagatctaa	agctcctttc	attttatact	gattaaatca	2460
	gtacttcagt	attttgattaa	aaaaaaaata	gcagattttg	tgattcttgg	gacttttttg	2520
65	acgtaagaaa	tacttcttta	tttatgcata	ttcttccac	agtgattttt	ccagcattct	2580
	tctgccatat	gccttttaggg	cttttataaa	atagaaaatt	aggcattctg	atatttcttt	2640

agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700  
 agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760  
 catccaccag taagcaagct ctgttaggct tccatgggta gtggtagctt ctctcccaca 2820  
 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880  
 5 ggtatgccag cacctgggta acagtaggag attttataca ttaatctgat ctgtttaatc 2940  
 tgatcggttt agtagagatt ttatacat

<210> 34  
 <211> 6011  
 10 <212> DNA  
 <213> Human

<400> 34

15

acggggcgcc ggacgaccgc cacatcttat cctccacgcc ccaactcgac tcggagcggg 60  
 accgccccgc actccccctc gggccgacca ctcgaggagt gaggagagag gccgccggcc 120  
 20 cggcttgagc cgagcgagc accccccgcg ccccgcgcca gaagtgtgtg tgaaccgggc 180  
 tgccgggaga aacttttttc ttttttcccc ctctcccggg agagtctctg gaggaggagg 240  
 ggaactcccc cgcccgaagg ctcggtggct cggggtcgcg cggccgcaga aggggcgggg 300  
 tccgccccgc aggggaggcg cccccgggga cccgagaggg gggtagggac cgcgggctgc 360  
 25 tgggtcgggc gcggcagcgt gtgccccgcg caggggaggc gccgccccgc tcccgccccg 420  
 gctgcgagga ggaggcgggc gcggcgaggg aggatgtact tgggtggcggg ggacaggggg 480  
 ttggcgggct gcgggcacct cctggtctcg ctgctggggc tgctgctgct gccggcgcg 540  
 tccggcaccg gggcgctggg ctgcctgccc tgtgacgagt ccaagtgcga ggagcccagg 600  
 aaccgccccg ggagcatcgt gcaggcgctc tgcggctgct gctacacgtg cgccagccag 660  
 gggaacgaga gctgcggcgg caccttcggg atttacggaa cctgcgacgg ggggctgcgt 720  
 30 tgtgtcatcc gcccccgct caatggcgac tccctcaccg agtacgaagc gggcgtttgc 780  
 gaagatgaga actggactga tgaccaactg cttggtttta aaccatgcaa tgaaaacctt 840  
 attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900  
 aatccctttg agttccaag tcaggatatg tgcctttcag ctttaaagag aattgaagaa 960  
 gagaagccag attgctccaa ggcgcgctgt gaagtccagt tctctccacg ttgtcctgaa 1020  
 35 gattctgttc tgatcgaggg ttatgtctct cctggggagt gctgtccctt acccagccgc 1080  
 tgcggtgtga accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140  
 ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaaacca 1200  
 gttttcggcg tggactgcag gactgtggaa tgcctactg ttcagcagac cgcgtgtccc 1260  
 ccggacagct atgaaactca agtcagacta actgcagatg gttgtgtgac ttgccaaca 1320  
 40 agatgcgagt gtctctctgg cttatgtggg ttccccgtgt gtgaggtggg atccactccc 1380  
 cgcatagtct cctgtggcga tgggacacct ggaaagtgtc gtgatgtctt tgaatgtgtt 1440  
 aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500  
 cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcc 1560  
 cagtgtgggt agataaactg cgagaggtac tacgtgcccg aaggagagtg ctgcccagt 1620  
 45 tgtgaagatc cagtgtatcc ttttaataat cccgtggct gctatgcaa tggcctgatc 1680  
 cttgcccacg gagaccggtg gcgggaagac gactgcacat tctgccagtg cgtcaacggt 1740  
 gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800  
 ggggagtggt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcatgt 1860  
 ggggagttat caaactgcac tctgacacgg aaggactgca ttaatggttt caaacgcgat 1920  
 50 cacaatggtt gtcggacctg tcagtgcata aacaccagg aactatgttc agaacgtaaa 1980  
 caaggctgca ccttgaactg tcccttcggg ttccctactg atgccccaaa ctgtgagatc 2040  
 tgtgagtgcc gcccaaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100  
 cttggattgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160  
 ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtacggy ctgtcttata 2220  
 55 tgcaagtgca gagaggcctc tgcctcagct gggccacca tctgtcggg cacttgtctc 2280  
 accgtggatg gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340  
 tactgtctca atggacggga aatgtgtgcc ctgatcacct gcccggtgcc tgccgtgtgc 2400  
 aacccacca ttcaccctgg acagtgtgc ccacatgtg cagatgactt tgtggtgcag 2460  
 aagccagagc tcagactcc ctccatttgc cagccccctg gagggagaata ctttgtggaa 2520  
 60 tgtagacag aggtgtgccc accgtgtctc tgccagaacc cctcacgcac ccaggattcc 2640  
 tgctgcccac agtgtacaga tcaacctttt cggccttcct tgtcccgcaa taacagcgta 2700  
 cctaattact gcaaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760  
 gacgttttga ccagctgcat ctgcattgat agcgtaatta gctgtttctc tgagtctgc 2820  
 65 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgttgcct ctactgcata 2880  
 aaagacacaa ttccaaagaa ggtgggtgtc cacttcagtg ggaaggccta tgccgacgag 2940

gagcgggtggg accttgacag ctgcacccac tgcactactgcc tgcagggcca gaccctctgc 3000  
 tcgaccgtca gctgcccccc tctgcccctgt gttgagccca tcaacgtgga aggaagtgc 3060  
 tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120  
 aaccatcgag gagagggtga cctggaggtt cccctgtggc ccacgcctag tgaaaatgat 3180  
 5 atcgtccatc tccctagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240  
 caccgaagtg aagattcttc actggactcc attgcctcag ttgtgggtcc cataattata 3300  
 tgccctctcta ttataatagc attcctattc atcaatcaga agaaacagtg gataccactg 3360  
 ctttgctggg atcgaacacc aactaagcct tcttctttaa ataactagct agtatctgtg 3420  
 gactgcaaga aaggaaccag agtccagggtg gacagttccc agagaatgct aagaattgca 3480  
 10 gaaccagatg caagattcag tggcttctac agcatgcaaa aacagaacca tctacaggca 3540  
 gacaatttct accaaacagt gtgaagaaag gcaactagga tgagggttca aaagacggaa 3600  
 gagcactaaa tctgctctaa aaagtaaaact agaatttgtg cacttgctta gtggattgta 3660  
 ttggattgtg acttgatgta cagcgctaa agccttactgg gatgggctct gtctacagca 3720  
 atgtgcagaa caagcattcc cacttttctt caagataact gaccaagtgt tttcttagaa 3780  
 15 ccaaagtttt taaagtgtgct aagatatatt tgcctgtaag atagctgtag agatatttgg 3840  
 ggtgggggaca gtgagtttgg atggggaaag ggggtggagg gtggtgttgg gaagaaaaat 3900  
 tggtcagctt ggctcgggga gaaacctggt aacataaaag cagttcagtg gccagagggt 3960  
 tatttttttc ctattgctct gaagactgca ctgggttctg caaagctcag gcctgaatga 4020  
 gcaggaaaca aaaaaggcct tgcgaccag ctgccataac caccttagaa ctaccagacg 4080  
 20 agcacatcag aaccctttga cagccatccc aggtctaaag ccacaagttt cttttctata 4140  
 cagtcacaa tgcagtaggc agtgaggaag ccagagaaat gcgatagcgg catttctcta 4200  
 aagcgggtta ttaagatat atacagttac actttttgtg gcttttattt tcttccaagc 4260  
 caatcaatca gccagttcct agcagagtca gcacatgaac aagatctaag tcatttcttg 4320  
 atgtgagcac tggagctttt tttttttaca acgtgacagg aagaggaggg agagggtgac 4380  
 25 gaacaccagg catttccagg ggctatatatt cactgtttgt tgttgctttg ttctgttata 4440  
 ttgttggttg ttcatagttt ttgttgaagc tctagcttaa gaagaaactt tttttaaaaa 4500  
 gactgtttgg ggattctttt tctttattat ataactgattc taaaaaatag aaactacttc 4560  
 attttaattg tatattattc aagcaccttt gttgaagctc aaaaaaatg atgcctcttt 4620  
 aaactttagc aattatagga gtattttatgt aactatctta tgcttcaaaa aacaaaagta 4680  
 30 tttgtgtgca tgtgtatata atatatatat atacatatat atttatacac atacaattta 4740  
 tgttttctcg ttgaatgtat ttttatgaga ttttaaccag aacaaaggca gataaacagg 4800  
 cattccatag cagtgccttt gatcacttac aaattttttg aataacacaa aatctcattc 4860  
 tacctgcagt ttaattggaa agatgtgtgt gtgagagtat gtatgtgtgt gtgtgtgtgt 4920  
 gtgtgtgctg gcgcacgcac gccttgagca gtcagcattg cacctgctat ggagaagggt 4980  
 35 attcctttat taaaatcttc ctcatttgga tttgctttca gttgggtttc aatttgctca 5040  
 ctggccagag acattgatgg cagttcttat ctgcactact aatcagctcc tggatttttt 5100  
 tttttttttt tcaaacaatg gtttgaacaa actactggaa tattgtccac aataagctgg 5160  
 aagtttgttg tagtatgcct caaatataac tgactgtata ctatagtggg aacttttcaa 5220  
 acagccctta gcacttttat actaattaac ccatttgtgc attgagtttt cttttaaaaa 5280  
 40 tgcttggtgt gaaagacaca gatacccagt atgcttaacg tgaaaagaaa atgtgttctg 5340  
 ttttgtaaag gaactttcaa gtattgtgtg aaataacttg acagagggtg ctgaacttta 5400  
 aaaaaaatat atttattatt ataataacct aatttattaa tctgaagatt aaccattttt 5460  
 ttgtcttaga atatcaaaaa gaaaaagaaa aagggtgttct agctgtttgc atcaaaggaa 5520  
 aaaaagattt attatcaagg ggcaatatatt ttatcttttc caaaataaat ttgttaatga 5580  
 45 tacattacaa aaatagattg acatcagcct gattagtata aattttgttg gtaattaatc 5640  
 cattcctggc ataaaaagtc tttatcaaaa aaaattgtag atgcttgctt tttgtttttt 5700  
 caatcatggc catattatga aaatactaac aggatataag acaagggtgta aattttttta 5760  
 ttattatttt aaagatatga tttatcctga gtgctgtatc tattactctt ttacttttgg 5820  
 tcctgttgtg ctcttgtaaa agaaaaatat aatttctgta agaataaaat agatatatgg 5880  
 50 cacttggagt gcatcatagt tctacagttt gtttttgttt tcttcaaaaa agctgtaaga 5940  
 gaattatctg caacttgatt cttggcagga aataaacatt ttgagttgaa atcaaaaaaa 6000  
 aaaaaaaaaa a

55 <210> 34a  
 <211> 1036  
 <212> DNA  
 <213> Human

60 <400> 34a

mylvagdrgl agcghllvsl lgllllpars gtralvclpc deskceepn rpgsivqgvc 60  
 gccytcasgg nescgggtfgi ygtcdrglrc virpplngds lteyeagvce denwtddqll 120  
 65 gfkpcnenli agcniingkc ecntirtcsn pfefpsqdmc lsalkrieee kpdcskarce 180  
 vqfsprcped svliegyapp gecclpsrc vcnpagclrk vcqpgnlnil vskasgkpgc 240

5 ccdlyeckpv fgvdertvec ptvqqtacpp dsyetqvrllt adgcctlptr ceclsglclgf 300  
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnv veyydgdmfr mdncrfrcrq 360  
 ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420  
 ctfcqcvnge rhcvatvcgq tctnrvkvpq eccpvceepi iitvdppacg elsncitlkr 480  
 dcingfkrdh ngcrtcqcin tqelcserkq gctlncpfgr ltdaagnceic ecrprpkkr 540  
 piicdkycpl gllknkhgdc icrckkcpel scskicplgf qgdshgcllc kreasasag 600  
 ppilsgtclt vdghhkhnee swhdgcrecy clngremcal itcpvpacgn ptihpgqccp 660  
 scaddfvvqk pelstpsich apggeyfvge etwnidsctq ctchsgrvlc etevcppllc 720  
 qnpsrtqdsq cpqctdqpfpr pslsrnnsvp nyckndegdi flaaeswkpd vctscicids 780  
 10 viscfesescp svscerpvlr kgqccpycik dtipkkvch fsgkayadee rwdldscsthc 840  
 yclgggtlcs tvscpplpcv epinvegsc pmcpemyvpe ptnipiekt nhrgevdlevp 900  
 lwptpsendi vhlprdmghl qvdyrdnrhl psedssldsi asvvvpiiic lsiiiaflfi 960  
 nqkkqwipll cwyrtpkps slnnqlvsvd ckkgrtvqv d ssqxmlriae pdarfsgfys 1020  
 15 mqkqnhlqad nfyqtv

&lt;210&gt; 35

&lt;211&gt; 716

&lt;212&gt; DNA

20 &lt;213&gt; Human

&lt;400&gt; 35

25 gcagtagctg gagggtcctg cagggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60  
 acccggggct cctggggccgc tctgcccggc tggggctgag cagcgatcct gctttgtccc 120  
 agaagttccag agggatcagc cccagaacac accctcctcc ccgggacgcc gcagctttct 180  
 ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240  
 30 ccagaactcg gtcctatttt acagattgag aaactatggg tcaagaagag aggacggggc 300  
 ttgagggaaat ctccctgattc tccttatatg acctcaaaact gaccatacta aacagtgtag 360  
 aaggctctttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420  
 gtcagtgtgg agtagacggg ttccctccacc cagggttgac tcagggggat gatctgggtc 480  
 ccattctggt ctttaagacc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540  
 tctggttagt gtcgtaacct ctgtgtgcct cccgttacct catctgtcca gtgagctcag 600  
 35 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660  
 gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

&lt;210&gt; 36

&lt;211&gt; 395

40 &lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 36

45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60  
 aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca tttactacat 120  
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaa atacttcaga ggctgaaaat 180  
 atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcaactttcac 240  
 gccagtaaaa accaaagtca gggttaacaa tgtcatttta caaaatgta aaacccta 300  
 50 tgcagttcct tttttaaatt attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360  
 agaagcaagg aaagcattct taattctacc atcct

&lt;210&gt; 37

&lt;211&gt; 134

55 &lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 37

60 ccctcgagcg gccgcccggg cagggtacttt taccaccgaa ttgttcactt gactttaaga 60  
 aaccataaa gctgcctggc tttcagcaac aggcctatca acaccatggg gactctccat 120  
 aaggacacc gtgt

&lt;210&gt; 38

65 &lt;211&gt; 644

&lt;212&gt; DNA

&lt;213&gt; Human

&lt;400&gt; 38

5 aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60  
cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120  
gggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180  
ggaatatttg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240  
gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300  
10 ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaga 360  
aggatgttta tggtccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420  
ttcgacccgg aaaatgtagc ttcccggtta agtaccttgg ccatgtagaa gttgatgaat 480  
caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagtctt 540  
tcaaaggcct ctttggaaaa actggaaaga aagcagttta agcagtttct gtgggtctaa 600  
15 gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat

&lt;210&gt; 39

&lt;211&gt; 657

&lt;212&gt; DNA

20 &lt;213&gt; Human

&lt;400&gt; 39

ctttttgttt gggttttcca atgtagatgt ctacagtgaat tgtgcagata tactttgttc 60  
25 cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120  
gcctcccatc taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180  
tagccagtggt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240  
acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300  
agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360  
30 tggctcctttg agcaaaatga gaagaaaaaa ttctgtcagc cagtattcac tgtgttaaga 420  
ttttttgttt ttacacgaa tggaaaaatg atgtgtaagt ggtatagatt ttaacagct 480  
aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540  
taagaaatac tactacattt aacattataa agtagagttc tggacataac tgaaaattag 600  
atgtttgctt caatagaaat ttgttccac ttgtattttc aacaaaatta tcggaac

35

&lt;210&gt; 40

&lt;211&gt; 1328

&lt;212&gt; DNA

&lt;213&gt; Human

40

&lt;400&gt; 40

acaattttta aataactagc aattaatcac agcatatcag gaaaaagtac acagtgaatt 60  
ctggttagtt tttgtaggct cattatgggt agggctcgta agatgtatat aagaacctac 120  
45 ctatcatgct gtagtatca ctcattccat ttcatgttcc catgcatact cgggcatcat 180  
gctaataatgt atccttttta gcactctcaa ggaacaaaaa gggcctttta tttttataaa 240  
ggtaaaaaaa attcccaaaa tttttgcat tgaatgtacc aaagggtgaag ggacattaca 300  
atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360  
acttcttca cagtgccttg tctaccacta caaggactgt gcatctaagt aataattttt 420  
50 taagattcac tataatgtat agtatgatat gcattttattt aaaaatgcatt agactctctt 480  
ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540  
gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600  
tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaattgaa 660  
actcagaact atattttctaa gcctgcattt tccatgatgc atactagtc ttacttctgc 720  
55 aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780  
ttaattttat gagaagggtat tcttcatatt aattgctttt gggattactc cacatctttg 840  
tttatttctt gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaaagc 900  
attggattga catatgggtt gccagcctat ggggtttacag gcattgcccc aacatttctt 960  
tgagatctat atttataagc agccatggaa ttccatttat gggatgttgg caatcttaca 1020  
60 tttttatagag gtcatatgca tagtttttcat aggtgttttg taagaactga ttgtctctct 1080  
gtgagtttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140  
ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggt tatagaaatc 1200  
tggaataaag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260  
65 ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320  
tgaaaaaa

<210> 41  
<211> 987  
<212> DNA  
<213> Human

5  
<400> 41

10 aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgtagg caggtaacat 60  
tgagctcttt tcaaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatgggtg 120  
taaccccccg ctatcagtcg ggatgggttg caccctcct gctgtaggat ggaagcagcc 180  
atggagtgag agggaggcgc aataagacac ccctccacag agcttgccat catgggaagc 240  
tggttctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300  
tgtctttctc ttctccaacc aacagaaaag actgctcttc aaagtgagg ggtcttcatg 360  
aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaagg agggcacaca 420  
15 ggaggaggga ggagctggta gggagatgct ggctttacct aaggtctcga aacaaggagg 480  
gcagaatagc cagaggcctc tccgtcccag gccattttt gacagatggc gggacggaaa 540  
tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600  
gaacaagcac aggccttgga atccaatgga ctgaatcaga accctaggcc tgccatctgt 660  
cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720  
20 tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggtatccaa 780  
aatagtctac ggccatacca ccctgaacgt gcctaatactc gtaagctaa cagggtcagg 840  
cctggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgcag ttggagttgg 900  
actctgtctt aacagtagcg tggcacacag aaggcactca gtaaatactt gttgaataaa 960  
tgaagtagcg atttggtgtg aaaaaaa

25  
<210> 42  
<211> 956  
<212> DNA  
<213> Human

30  
<400> 42

35 cggacggtgg ggcggacgcg tgggtgcagg agcagggcgg ctgccgactg ccccaaccaa 60  
ggaaggagcc cctgagtcgg cctgcgcctc catccatctg tccggccaga gccggcatcc 120  
ttgctgtgt aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180  
tcaggggatg tttacctggt gctcgggaag ggaggggaag gggccgggga gggggcacgg 240  
caggcgtgtg gcagccacac gcaggcggcc agggcgccca gggacccaaa gcaggatgac 300  
cacgcacctc cagccactg cctccccga atgcatttgg aaccaaagtc taaactgagc 360  
tcgcagcccc cgccgctcc ctccgctcc catcccgctt agcgtctgtg acagatggac 420  
40 gcaggccctg tccagcccc agtgcgctcg ttccggtccc cacagactgc cccagccaac 480  
gagattgtgt gaaaccaagt caggccaggt gggcggaaca aaggggcagg tgccgctgtg 540  
ggggaacgga tgctccgagg actggactgt tttttcaca catcggttgc gcagcggtg 600  
gaaggaaagg cagatgtaaa tgatgtgtt gtttacaggg tatattttt ataccttcaa 660  
tgaattaaat cagatgtttt acgcaaggaa ggacttacct agtattactg ctgctgtgct 720  
45 tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcgggt accccatcac 780  
tcgcaggacc aaggggggcg ggactgctgg ctcacgcccc gctgtgtcct ccctccctc 840  
ccttccttgg gcagaatgaa ttcatgtcgt attctgtggc cgccatctgc gcagggtggt 900  
ggtattctgt catttacaca cgtcgttcta attaaaaagc gaattatact ccaaaa

50  
<210> 43  
<211> 536  
<212> DNA  
<213> Human

55  
<400> 43

60 aaataaacac ttccataaca tttgttttc gaagtctatt aatgcaatcc cacttttttc 60  
cccctagttt ctaaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120  
agtgttagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180  
ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240  
tctaaataaa gacatttgaa gggttagttt gaattctaaa agtaggtaat agccaaatag 300  
cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaaat 360  
attttttcca gatgaaactt gtgccacttc caattgacta atgaaatata aggagacaga 420  
ctggaaaaag tgggttatgc cacctttaaa accctttctg gtaaatatta tggtagctaa 480  
65 aggggtgggtt ccccggcacc tggacctgga caggtagggt tccgtgggtt accagt



<210> 44  
 <211> 1630  
 <212> DNA  
 <213> Human

5

&lt;400&gt; 44

10 ggggagggac gagtatggaa ccctgaaggt agcaagtcca ggcaactggcc tgaccatccg 60  
 gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120  
 tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180  
 atccccctctg gaggggaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240  
 ccatcccgagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300  
 gtgatttccc ttagggcccag gacttgggcc tccagctcat ctgttccttc tggggccatt 360  
 catggcagggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420  
 15 gactttacct gattgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480  
 tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540  
 gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgat 600  
 attaggaagt cgggggtggg tgggtgggtgg gggctagtgg gggttgaatt taggggccga 660  
 tgagcttggg tacgtgagca ggggtgtaag ttagggtctg cctgtatttc tgggtcccctt 720  
 20 ggaaatgtcc ccttcttcag tgtcagacct cagtcaccagt gtccatatcg tgcccagaaa 780  
 agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgccctgt 840  
 gcccagtgac ctgggggagc ctggctgcag gccctcactg gttccctaaa ccttgggtggc 900  
 tgtgattcag gtccccaggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960  
 25 gaggttggctg gtagagcctt ctagagggttc agaataatag cttcaggatc agctgggggt 1020  
 atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080  
 tgagggacag tttgggtttg ggacttacca ggggtgatgt agatctggaa cccccaagt 1140  
 aggtctggagg gaggtaaggt cagtatggaa gatagggttg ggacagggtg ctttggaatg 1200  
 aaagagtgc cttagagggc tccttgggcc tcaggaatgc tcctgctgct gtgaagatga 1260  
 gaaggtgctc ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320  
 30 ctgggtccct ttagcacag gagactggg ctaagggcc ctcccaggga agggacacca 1380  
 tcaggcctct ggctgaggca gtagcataga ggatccatt ctacctgcat ttcccaggag 1440  
 actagcagga gccagccttg agaaaccggc agttcccaag ccagcgcctg gctgttctct 1500  
 cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560  
 35 cctcttgcct cttgtagaat gcagctctgg ccctcaataa atgcttcctg cattcatctg 1620  
 caaaaaaaaa

<210> 45  
 <211> 169  
 <212> DNA  
 <213> Human

40

&lt;400&gt; 45

45 tcttttgcct ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60  
 taaaactggg ttatgatctt cagtctgatt ccagtgtctg ataactagat aacgtatgaa 120  
 ggaaaaacga cgacgaacaa aaaagtaagt gcttgaaga cttagttaga

50 <210> 46  
 <211> 769  
 <212> DNA  
 <213> Human

&lt;400&gt; 46

55 tgcaggtcat atttactatc ggcaataaaa ggaagcaaag cagtattaag cagcgggtgga 60  
 atttgcctgt ttacttttt ataaagtgtc acataaaatg tcatatttcc aaatttaaaa 120  
 acataactcc agttcttacc atgagaacag catggtgatc acgaaggatc ttcttgaaaa 180  
 aaacaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagatata 240  
 aaggtgtact aggcattctt agagatctgg caacttattt tataatataag gcatctgtga 300  
 60 ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaatgcaag 360  
 cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420  
 ggccagctcc tttcctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480  
 catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540  
 tattttgtaa taaaatcaaa tttccattg aaaccttcaa aaactttgca gaatgaggtt 600  
 65 ttgatatatg tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660  
 cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47  
 <211> 2529  
 5 <212> DNA  
 <213> Human

<400> 47

10 tttagtcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaaca 60  
 gtgaaaatta gtgactggtt aaggtgtgcc actgtacata tcatcatttt ctgactggg 120  
 tcaggacctg gtcctagtc acaagggtgg caggaggagg gtggaggcta agaacacaga 180  
 aaacacacaa aagaaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240  
 15 ggatggtggg aaggggggtc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300  
 gccttactta gctcctggca gaggtgaggt ggggacctac gaggttcaaa atcaaatggc 360  
 atttgggccag cctggcttta ctaacaggtt ccagagtgct ctctgttggc tgagctctcc 420  
 tgggtcact ccatttcatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480  
 attattcttc tggaaaccca tttctgttga gtccatctga cttaagtcct ctctccctcc 540  
 actagtggg gccactgcac tgaggggggg cccaccaatt ctctctagag aagagacact 600  
 20 ccagaggccc ctgcaacttt gcggatttcc agaagggtgat aaaaagagca ctcttgagtg 660  
 ggtgcccagg aatgttttaa atctatcagg cacactataa agctggtggt ttcttctact 720  
 caagtggatt cggcataatga accacctact caatacttta tattttgtct gtttaaacac 780  
 tgaactcttg tgttgacagg tacaaggag aagagatggg gactgtgaag aggggagggc 840  
 ttccctcatc ttctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900  
 25 gcaatagatg gggcttccca ccatttgttg gttattgctg gggtagcca ggagcagtg 960  
 ggatggcaaa gtaggagaga ggcccagagg aaagccatc tccctccagc tttggggtct 1020  
 ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080  
 aggtgaacag tcctacctgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140  
 ttatgaaact gaaaatcaaa tcaaggtatt gggagaata atttcccctc gattccacag 1200  
 30 gaggaagac cacacaatat cattgtgctg gggctcccca aggcctgcc acctggcttt 1260  
 acaaatcatc aggggttgcc tgcttggcag tcacatgctt ccctggtttt agcacacata 1320  
 caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380  
 ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatggtgg tcttttgcat 1440  
 gcagttggg tgacctgaca aagccccagc tttctgtggc caggttctgg gagaggatgc 1500  
 35 attcaagctt ctgcagccta ggggacaggg ctgcttgttc agttattact gcctcggagc 1560  
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620  
 cttcggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680  
 agggagaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740  
 tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800  
 40 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860  
 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920  
 gggggagtgg gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980  
 ctctatctga ggagcccca ctggcttcag aagcaactta ccaaggggta ttaaagaca 2040  
 tgaaaatttc cagaaatacc atttggtgca tccctttgtt tctgtaatat taaactcagg 2100  
 45 tgaaattata ctctgacagt ttctctcttc ctgctcttcc cctctgcaga gtcaggacct 2160  
 gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaa 2220  
 gcctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactgggtc 2280  
 tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340  
 ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg caggtcacca 2400  
 50 gtccagagcc ctgccacgga tgtacgcagg agcccagcat taggcaatca ggagccagaa 2460  
 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520  
 ggggtgtcc

<210> 48  
 55 <211> 1553  
 <212> DNA  
 <213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60  
 ttcatatata tatatacata catatataaa ggaaacaatt tgcaatttta cacacctgac 120  
 aaaaccatat atacacacac atgtatgcat acacacagac agacacacac accggaagct 180  
 ctaggccaggc ccgtttttcca tccctaagta ccattctctc atttggggcc ttctagggtt 240  
 65 ggggcccctga gcttggtttg tagaagtttg gtgctaatat aaccatagct ttaatcccca 300  
 tgaaggacag tgtagacctc atctttgtct gctcccgcgt gcctttcagt tttacgtgat 360

5 ccatacaagag ggctatggga gccaaagtga caccgggggat tgaggctaata tcacctgaac 420  
 tcgaaaacag cggccagctt cctcaccgca ggcacgcgtc ttttcttttt ttttcctcga 480  
 gacggagctc cgctgtgttg cccaggctgg agtgacgtgg caccgtctcg gctcactgca 540  
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600  
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660  
 caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgcccgcct cggcctccca 720  
 aagtgtctgg attacaggcg tgagccacca cactgggccc cggcacgtat cttttaagga 780  
 atgacaccag ttctgtgctt ctgaccaaag aaaaaatgtc acaggagact ttgaagagge 840  
 agacaggagg gtggtggcag caacactgca gctgcttctg gatgctgctg ggggtgctctc 900  
 10 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtctctc 960  
 acttcagtgg tgcacctgga tgggtggaagc cagccttttg ggcaggaaac cagctcagag 1020  
 aggtacccca gctcagctgc tggcaggagc caggtattta cagccataat gtgtgtaaag 1080  
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140  
 ggatgagctt cactcaacgt ggagatgggt gtggactggg ccctgaaaag cgggctcttg 1200  
 15 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260  
 cgaggggagc agggagcttc tctctagtcc ctttgagggc tttggctgag agaagagtga 1320  
 gcagggagct gggaatggtc caggcaggga agggagctga agtgattcgg ggctaattgc 1380  
 tcagatcgat gtatttctct ccctgggtctc cggagccct cttgtcaccg ctgctgccct 1440  
 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500  
 20 tacgagaccg ggggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

&lt;210&gt; 49

&lt;211&gt; 921

&lt;212&gt; DNA

25 &lt;213&gt; Human

&lt;400&gt; 49

30 ctgtggtccc agctactcag gaggetgagg cgggaggatt gcttgagccc aggagttgga 60  
 tgttgacgtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120  
 gtctcagaaa acaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180  
 gcctgtcaga acacttggtt actcctaccc cagatcagtg gacctgggaa tgagggttgg 240  
 tcccgggagg cttttctcca agctgttgcc accagaccgg ccatgggaa cctggccaca 300  
 gaagcctccc ggggagtgag ccagagcctg gaccgctgtg ctgatgtgtc tgggggtggag 360  
 35 ggaggggtgg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatt ggcaagcatg 420  
 tgctgtcctg tgtgtgtgcg tgccccctcc ctgcagccgt cgggtggtatc tccctccagc 480  
 cccttcgcca ccttctgagc attgtctgtc cagtgagac tgcccagaga cagcagagct 540  
 ccacgtgggt ttaaggggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600  
 caggtgtctaa atgacccgac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660  
 40 gtcccgtgta cctgcccccg tggcgtctca cggatgagcc tgctcctgac attgggtgtt 720  
 actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780  
 ttcaaataaa atggacttga tttagaaagc caaaaagctg tgtggtcctt ccagcacgga 840  
 tactttgacc tcttgcttac aacccttccc ttgggtccga ggctggtagc tttgttccact 900  
 tcagatgggt gggggcgggt g

45 &lt;210&gt; 50

&lt;211&gt; 338

&lt;212&gt; DNA

&lt;213&gt; Human

50 &lt;400&gt; 50

55 atgatctatc tagatgccct accgtaaaat caaaacacaa aaccctactg actcattccc 60  
 tcccttcag atattacccc atttctctac ttcccattgt agccaaactt tccaaaaatt 120  
 catgttctgt cttcatttcc tcatgttcaa cccaccctgt cttagctacc accctcagt 180  
 aacgacctag cctgggtaga aacaaatgtc agcatgatac cataactcaat gatccttctg 240  
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgcata 300  
 gtaagaaact ttctttcttg aattcttggg tctcttgg

60 &lt;210&gt; 51

&lt;211&gt; 1191

&lt;212&gt; DNA

&lt;213&gt; Human

65 &lt;400&gt; 51

	ctagcaagca	ggtaaacgag	ctttgtacaa	acacacacag	accaacacat	ccggggatgg	60
	ctgtgtgttg	ctagagcaga	ggctgattaa	acactcagtg	tgttggtct	ctgtgccact	120
	cctggaaaat	aatgaattgg	gtaaggaaca	gttaataaga	aaatgtgcct	tgctaactgt	180
	gcacattaca	acaaagagct	ggcagctcct	gaaggaaaag	ggcttgtgcc	gctgccgttc	240
5	aaacttgtca	gtcaactcat	gccagcagcc	tcagcgtctg	cctccccagc	acaccctcat	300
	tacatgtgtc	tgtctggcct	gatctgtgca	tctgctcggg	gacgctcctg	acaagtcggg	360
	aatttctcta	tttctccact	ggtgcaaaga	gcggtattct	ccctgcttct	cttctgtcac	420
	ccccgtcct	ctccccag	aggctccttg	atttatggta	gctttggact	tgcttccccg	480
	tctgactgtc	cttgacttct	agaatggaag	aagctgagct	ggggaaggga	agactccagg	540
10	ccatcacaga	taaaagaaaa	atacaggaag	aaatctcaca	gaagcgtctg	aaaatagagg	600
	aagacaaact	aaagcaccag	catttgaaga	aaaaggcctt	gagggagaaa	tggcttctag	660
	atggaatcag	cagcggaaaa	gaacaggaag	agatgaagaa	gcaaaatcaa	caagaccagc	720
	accagatcca	ggttctagaa	caaagtatcc	tcaggcttga	gaaagagatc	caagatcctg	780
	aaaaagctga	actgcaaata	tcaacgaagg	aagaggccat	tttaaagaaa	ctaaagtcaa	840
15	ttgagcggac	aacagaagac	attataagat	ctgtgaaagt	ggaaagagaa	gaaagagcag	900
	aagagtcaat	tgaggacatc	tatgctaata	tccctgacct	tccaaagtcc	tacatacctt	960
	ctagggttaag	gaaggagata	aatgaagaaa	aagaagatga	tgaacaaaat	aggaaagctt	1020
	tatatgccat	ggaaattaaa	gttgaataag	acttgaagac	tggagaaaag	acagttctgt	1080
	cttccaatac	ctctggccat	cagatgactt	taaaagggtac	aggagtaaaa	gtttaagatg	1140
20	atggggcaaaa	gtccagtgta	ttcagtaaag	tgctaatac	aagttggagg	t	
	<210>	52					
	<211>	1200					
	<212>	DNA					
25	<213>	Human					
	<400>	52					
	aacagggact	ctcactctat	caaccccagg	ctggagtcg	gtgcgccac	cctggctccc	60
30	tgcaacctcc	gctcccag	ctcaagcaac	tctcctgcct	cagtcgctct	agtagctggg	120
	actacaggca	cacaccacca	tgcccagcca	atttttgcat	ttttttaga	gacagggttt	180
	cgccttctgt	ccaggccggc	atcatatact	ttaaatcatg	cccagatgac	tttaatacct	240
	aatacaatat	atcaggttgg	tttaaaaata	attgcttttt	tattattttt	gcatttttgc	300
	accaacctta	atgctatgta	aatagttgtt	atactgttgc	ttacaacag	tatgacaatt	360
35	ttggcttttt	ctttgtatta	ttttgtattt	ttttttttta	ttgtgtggtc	tttttttttt	420
	ttctcagtgt	tttcaattcc	tccttgggtg	aatccatgga	tgcaaaaacc	acagatatga	480
	agggtctggc	atatatgcat	tgatgattgt	cctattatat	tagttataaa	gtgtcattta	540
	atatgtagt	aaagtattgg	tacagtggaa	agagttagtg	aaaacataaa	catttggacc	600
	tttcaagaaa	ggtagcttgg	tgaagttttt	caccttcaaa	ctatgtccca	gtcagggctc	660
40	tgctactaat	tagctataat	ctttgcacaa	attacatcac	ctttgagtct	cagttgcctc	720
	acctgtaaaa	tgaaagaact	ggatactctc	taaggctact	tccagccctg	tcattctata	780
	actctgttat	gctgaggaag	aaattcacat	tgtgttaact	gtatgagtca	aactgaaaat	840
	gattattaaa	gtgggaaaaa	gccaatgtct	tctcttagaa	agctcaacta	aatttgagaa	900
	gaataatctt	ttcaattttt	taagaattta	aatattttta	agggtttgac	ctattttatt	960
45	agagatgggg	tctcactctg	tcacccagac	tggagtacag	tggcacaatc	atagctcact	1020
	gctgcctcaa	attcatgggc	tcaagtgtac	ctcctgcctc	tgccctccaga	gtagctgcga	1080
	ctatgggcat	gtgccaccac	gcctggctaa	catttgtatt	gacctattta	tttattgtga	1140
	tttatatctt	tttttttttt	tctttttttt	ttttttacaa	aatcagaaat	acttattttg	1200
50	<210>	53					
	<211>	989					
	<212>	DNA					
	<213>	Human					
55	<400>	53					
	aagccaccac	tcaaaacttc	ctatacattt	tcacagcaga	gacaagtga	catttatttt	60
	tatgcctttc	ttcctatgtg	tatttcaagt	ctttttcaaa	acaaggcccc	aggactctcc	120
	gattcaatta	gtccttgggc	tggtcgactg	tgccaggagtc	cagggagcct	ctacaaatgc	180
60	agagtgtact	tttaccaca	taaaccctag	atacatgcaa	aaagcaggac	ccttctctca	240
	ggaatgtgcc	atttcagatg	cacagcacc	atgcagaaaa	gctggaattt	tccttggaac	300
	cgactgtgat	agaggtgctt	acatgaacat	tgctactgtc	tttctttttt	tttgagacag	360
	gtttcgcttg	tgcccaggct	gagtgaatg	cgtgatctca	ctcactgcaa	ttccacctcc	420
	aggttcaagc	attctcctgc	tcagcctcct	agtagctggg	ttacaggcac	tgccacctg	480
65	ccggctaatt	ttgtattttt	gtagagatgg	atttctccat	ttggctcaggc	ggctctcgaa	540
	cccaacctca	gtgatctgcc	acctcagcct	cctaagtgtt	ggattacagg	atgagccacc	600

cgaccggcca ctactgtctt tctttgaccc ttccagtttc gaagataaag aggaaataat 660  
ttctctgaag tacttgataa aatttccaaa caaaacacat gtccacttca ctgataaaaa 720  
atttaccgca gtttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaaagag 780  
ttaagatttc ttcagcaaaa tagatgattc acatcttcaa gtcctttttg aaatcagtta 840  
5 ttaatattat tctttcctca ttcccatctg aatgactgca gcaatagttt tttttttttt 900  
tttttttttt ttgcgagatg gaatctcgtc ctgtcgccca gcgggagtg c actggcgcaa 960  
gcccggtca ccgcaatctc tgccacccg

<210> 54  
10 <211> 250  
<212> DNA  
<213> Human

<400> 54  
15 catttcccca ttggtcctga tgttgaagat ttagttaaag aggctgtaag tcaggttcga 60  
gcagaggcta ctacaagaag tagggaatca agtccctcac atgggctatt aaaactaggt 120  
agtgggtggag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcagggg 180  
aaagggcatt ctttaggaac tgcattctggt aacccacacc ttgatccaag agctagggaa 240  
20 acttcagttg

<210> 55  
<211> 2270  
<212> DNA  
25 <213> Human

<400> 55  
30 gcgcccccca gcagcgcccc cgccctccgc gccttctccg ccgggacctc gagcgaaga 60  
ggccccgcgc cgccccagcc ctgcctccc tgcccacccg gcacaccgcg ccgccacccc 120  
gaccccgctg cgcacggcct gtccgctgca caccagcttg ttggcgtctt cgtcgccgcg 180  
ctcgccccgc gctaactctg cgcgccaca tgagctcccg catcgccagg gcgctcgctt 240  
tagtcgtcac ccttctccac ttgaccaggc tggcgtctc cacctgcccc gctgcctgcc 300  
actgccccct ggaggcgccc aagtgcgcgc cgggagtcgg gctggctccg gacggctgcg 360  
35 gctgctgtaa ggtctgcgcc aagcagctca acgaggactg cagcaaaacg cagccctgcg 420  
accacacca ggggctggaa tgcaacttcg gcgccaagtc caccgctctg aaggggatct 480  
gcagagctca gtcagagggc agaccctgtg aatataactc cagaatctac caaaacgggg 540  
aaagtttcca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600  
ttcctctgtg tcccaagaa ctatctctcc ccaacttggg ctgtcccaac cctcggtcgg 660  
40 tcaaagttac cgggcagtg cgcgaggagt gggctctgta cgaggatagt atcaaggacc 720  
ccatggagga ccaggacggc ctccctggca aggagctggg attcgatgcc tccgaggtgg 780  
agttgacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggctcc 840  
ctgtttttgg aatggagcct cgcacccctt acaacccttt acaaggccag aaatgtattg 900  
ttcaaacac ttcatggtcc cagtgtctca agacctgtg aactgggtatc tccacacgag 960  
45 ttaccaatga caaccctgag tgccgccttg tgaaaagaaac ccggatttgt gaggtgcggc 1020  
cttgtggaca ccagtgtag agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080  
aatccccga accagtcagg tttacttacg ctggatgttt gagtgtgaag aaataccggc 1140  
ccaagtactg cggttcctgc gtggacggcc gatgctgcac gcccagctg accaggactg 1200  
tgaagatgcg gttccgctgc gaagatgggg agacattttc caagaacgct atgatgatcc 1260  
50 agtccctgca atgcaactac aactgccccg atgccaatga agcagcgttt cccttctaca 1320  
ggctgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380  
cctagacaaa caaggagaa gagtgtcaga atcagaatca tggagaaaat gggcgggggg 1440  
gggtgtgggtg atgggactca ttgtagaaag gaagccttgc tcattcttga ggagcattaa 1500  
55 ggtatttcga aactgccaa ggtgctgggt cggatggaca ctaatgcagc cagcattgga 1560  
gaataacttg cttcatagta ttggagcaca tgttactgct tcatttttga gcttgtggag 1620  
ttgatgactt tctgttttct gtttgtaaat tatttgctaa gcatattttc tctaggcttt 1680  
tttctttttg gggttctaca gtcgtaaaag agataataag attagtttga cagtttaaaag 1740  
cttttattcg tcccttgaca aaagtaaatg ggagggcatt ccatcccttc ctgaaggggg 1800  
acactccatg agtgcctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860  
60 ggtgttttaa gactgaatgt tttatttatc aaaatgtagc ttttggggag ggaggggaaa 1920  
tgtaatactg gaataatttg taaatgattt taattttata ttcagtgaag agattttatt 1980  
tatggaatta accatttaat aaagaaatat ttacctaata tctgagtgtg tgccattcgg 2040  
tattttttaga ggtgtcccaa agtcatttag aacaacctag ctacgtact caattattca 2100  
aacaggactt attgggatac agcagtgtaat taagctatta aaataagata atgattgctt 2160  
65 ttataccttc agtagagaaa agtcttttga tataaagtaa tgttttaaaa acatgtattg 2220  
aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa

<210> 56  
<211> 1636  
<212> DNA  
5 <213> Human

<400> 56

```
10 cttgaatgaa gctgacacca agaaccgcgg gaagagcttg ggcccaaagc aggaaagggg 60
   agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccccac 120
   cagtttgatt ggaagtccag ctgtgaaacc tggagcgtcg ccttctcccc agatggctcc 180
   tggtttgctt ggtctcaagg acactgcata gtcaaaactga tccoctggcc gttggaggag 240
   cagttcatcc cttaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaaggg 300
   cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360
15 agcccgtggc cttccccacc cagcaggaag ctctgggcac gccaccaccc ccaagtggcc 420
   gatgtctctt gcctggttct tgctacggga ctcaacgatg ggcagatcaa gatctgggag 480
   gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
   agcttcacac ccagtggcag tttgattttg gtctccgcgt cacgggataa gactcttcgc 600
   atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcggggcca cctgcagtgg 660
20 gtttactgct gttccatctc cccagactgc agcatgctgt gctctgcagc tggagagaag 720
   tcggctcttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
   agcagtgttg tctcttgta cttctcccc gactctgccc tgcttgctac ggcttcttac 840
   gataccaatg tgattatgtg ggacccctac accggcgaaa ggctgaggte actccaccac 900
   acccaggttg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
25 tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
   tggggccctg aactgaaaac tcccattgca tttgctccta tgaccaatgg gctttgctgc 1080
   acatttttcc cactgggtgg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
   tggacagctc ctagggtcct gtctcactg aagcacttat gccggaaagc ccttcgaagt 1200
   ttcttaacaa cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagttcctc 1260
30 acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatcgt 1320
   cctgtcaaag ggagttgctg gaataatggg ccaaacatct ggtcttgcat tgaaatagca 1380
   tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
   tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500
   aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
35 aagatggtga aggggtggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
   gaccctgtgc tgcgtt
```

<210> 57  
<211> 460  
40 <212> DNA  
 <213> Human

<400> 57

```
45 ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60
   gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120
   tggaatgagc taaagcagcc gcctggggtg ggaggccgag ccattttgta tgcagcaggg 180
   ggcaggagcc cagcaaggga gcctccattc ccaggactct ggagggagct gagaccatcc 240
   atgcccgcag agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300
50 aactgaggct gggaagtcac atagcaagtg actggcagag ctgggactgg aaccaacca 360
   gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420
   ccgagctcga attcgtaatc atggctcatag ctgtttcctg
```

<210> 58  
55 <211> 1049  
 <212> DNA  
 <213> Human

<400> 58

```
60 atctgatcaa gaatacctgc cctgggtcact ctgcggatgt ttctgtccac ttgttcacat 60
   tgaggaccaa gatatacctt ttacagagg cacttggtcg gtctaacaca gacacctcca 120
   tgacgacatg ctggctcaca ttttgacagt ctgcagaagt cccctccca gcctggacta 180
   cagcagcact ttcccgtggg ggtgcagtag cgttttcgac agagcctgga gcactctgaa 240
65 gtcagtgtct gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
   ggatctacaa tttttagtag ttttcattg tgagtctggg tcatactttt actgcttgat 360
```

5    aaaaatgtaaa cttcacctag ttcattcttct ccaaattccca agatgtgacc ggaaaagtag 420  
      cctctacagg acccactagt gccgacacag agtggttttt cttgccactg ctttgtcaca 480  
      ggacttttgc ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540  
      aatcttttctg actggcagcc ccggtataca aatccaccaa ccaaaggacc attactgaat 600  
      ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660  
      attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720  
      tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780  
      aacacttcgg ggggctggtt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840  
 10    ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900  
      aacccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960  
      aaaaacccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gaggttctgca 1020  
      acttcaagaa agactctggc tgttctcaa

15    <210> 59  
      <211> 747  
      <212> DNA  
      <213> Human

20    <400> 59

25    tttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60  
      ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120  
      cttaaatata atgtatcata ccaacccaag taaaccaagt acaaaaaata ttcatataaa 180  
      gttgttcaca cgtagggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240  
      atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300  
      ctggtctgtc ccacacaaat gtttaagaag tcaactgcaat gtactccccg gctctgatga 360  
      aaagaagccc ctggcacaaa agattccagt gccctgaag aggctccctt cctcctgtgg 420  
      gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480  
      ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540  
 30    ccaattcaat gccacaccta ctggttacct tttgagggca tttctccaga cagaagcccc 600  
      ttgaagccta ggtagggcag gatcagagat acaccgtgt ttgtctcgaa gggctccaca 660  
      gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720  
      cgccaattta gtagtaatag cggccgc

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**